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Abstract 
During development the extracellular matrix is cleaved and remodeled to facilitate the 
large-scale cell rearrangements that are necessary for processes like gastrulation, neurulation, 
angiogenesis and organogenesis. ECM remodeling occurs primarily through secreted 
enzymes called matrix metalloproteinases (MMPs). Regulation of MMP activity is achieved 
through the tissue inhibitor of metalloproteinases (TIMPs), a small family of secreted 
proteins that bind MMPs in a 1:1 manner to inhibit their activity. Although TIMPs were 
originally characterized based on their MMP-inhibitory activities, in vitro studies have 
revealed that TIMPs are multifunctional proteins, with structurally and functionally distinct 
N- and C-terminal domains. TIMP N-terminal domains bind to and inhibit MMPs, whereas 
their C-terminal domains have cell signaling activity in apoptosis, cell migration and cell 
proliferation pathways. Using Xenopus laevis as a model organism, this study examined the 
unique roles of the TIMP N- and C-terminal domains during development to investigate the 
balance between TIMP MMP-inhibitory activity and signaling activity in vivo. 
Microinjection was used to overexpress the three X. laevis TIMPs or their individual domains 
in early stage embryos. This research demonstrated that the balance between MMPs and 
inhibitors in the ECM is very important, and that the ECM functions as an intricate network. 
Here I showed that the TIMP-1 and -2 C-terminal domains downregulated MMP 
expression/activity within this network independent of MMP-inhibition. Additionally the 
TIMP-1 and -2 C-domains altered signaling markers including caspase-3 and RECK, which 
was not observed with N-domain constructs, and resulted in severe developmental defects. In 
contrast, the TIMP-3 C-terminal domain performed no independent role in development. 
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This research is the first comprehensive comparison of TIMP domain function in vivo, and 
demonstrates for the first time a role for TIMP signaling during development. 
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Learn as if you were to live forever.” 
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CHAPTER 1 
GLOBAL INTRODUCTION AND LITERATURE REVIEW 
 
 
 
 
 
 
 
 
 
 
 
 
 2 
1.1 The Extracellular Matrix 
This work will examine the roles played by secreted enzymes and inhibitors that 
regulate protein dynamics outside of cells.  When one considers the myriad of functions 
performed by the many tissues and organs within the body, these functions are often 
attributed solely to cells. The tissues found in multicellular organisms, however, are not 
composed exclusively of cells; rather, cells are embedded in an extracellular matrix (ECM) 
that is essential for tissue and organ function. The ECM is a dynamic, complex network of 
interacting macromolecules that both surrounds and structurally supports cells. As such, the 
ECM is necessary for preserving tissue integrity in multicellular organisms. Additionally, the 
bidirectional interactions that exist between cells and the ECM are important for coordinating 
cellular functions. Communication with the ECM allows cells to perceive their changing 
environment and adapt in an appropriate manner (Bissell, Hall et al. 1982). The nature, 
regulation, and complexity of the exchanges between cells and the ECM are becoming 
increasingly significant in the study of both development and disease. In this chapter, I will 
begin by discussing the structural components of the ECM, and the roles of secreted enzymes 
and their inhibitors in remodeling of the ECM. I will subsequently discuss the contributions 
of these ECM remodeling proteins to the regulation of cancer progression, and most pertinent 
to my research, embryonic development.  
 
1.1.1. General structure of the ECM 
One of the primary functions of the ECM is to provide the histoarchitecture necessary 
for organ function and homeostasis (Aumailley and Gayraud 1998). Accordingly, the ECM is 
composed predominantly of large structural proteins. The proteins that form the ECM are 
secreted by cells embedded within the matrix, and are subsequently assembled into a 
 3 
precisely organized network that associates with cellular surfaces (Hays 1991). There are two 
main structural classes of proteins that make up the ECM: proteoglycans and large fibrous 
proteins. Proteoglycans are large hydrophilic molecules that consist of a protein core linked 
to polysaccharide chains termed glycosaminoglycans (GAGs). Large fibrous proteins such as 
collagen, elastin, fibronectin, and laminin are mainly structural in nature, although these 
proteins also have crucial non-structural functions such as facilitating cell migration and cell 
signaling. Variations in the arrangement and relative amounts of different ECM 
macromolecules govern, and can also alter the character of, the ECM (Frantz, Stewart et al. 
2010). In animal tissues, the ECM is found in two main forms: basement membrane (BM) 
and stromal matrix. Basement membranes are thin layers of defined ECM molecules that 
underlie epithelial cell sheets. The BM anchors the epithelium, serves as a barrier separating 
epithelial cells from the underlying connective tissue, polarizes cells, and regulates cell 
behavior (Nelson and Bissell 2006). In contrast, the stromal matrix contains abundant ECM 
with comparatively few embedded cells, and is associated with connective tissues including 
cartilage and bone. Stromal matrix is rich with proteoglycans, which form a hydrated gel-like 
mesh due to their hydrophilic nature. Within this gel-like matrix are fibrous proteins such as 
collagen and elastin, which provide strength to the stroma of tissues including tendons, 
cartilage, skin, and artery walls (Frantz, Stewart et al. 2010). 
It was originally thought that the ECM plays a passive role in mediating tissue and 
organ function, acting only as a framework to provide structural support for tissues. We now 
know that the ECM is exceedingly active, and interactions between cells and the ECM are 
now recognized as important factors in the regulation of cell behavior. In all tissues, cells are 
stably linked to the ECM. Although the composition of the ECM may vary from mainly 
collagen II in cartilage and bone, to laminin and collagen IV in the BM of epithelia, cells are 
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capable of sensing and responding to changes in the ECM. If the BM is removed from 
epithelia, for example, the cells will either migrate or undergo apoptosis, depending on their 
developmental fate. Furthermore, the organization of the ECM is both highly ordered and 
varied, such that the ECM structure and composition is specifically altered and adapted to 
serve the functional requirements of different tissues (Frantz, Stewart et al. 2010).  For 
instance, the ECM found in joints is important in maintaining hydration, in tendons the ECM 
provides strength, in kidneys the ECM is involved in filtration, and in the embryo, the ECM 
facilitates migration (reviewed in Frantz et al., 2010).  
 
1.1.2.  The ECM facilitates cell migration via integrins and focal adhesion structures 
Cell migration in tissues is dependent upon cell contact with the ECM. Cells cannot 
migrate freely through extracellular space; rather, motility depends on the ability of a cell to 
form adhesions with specific ECM substrates like fibronectin or laminin, which serve 
functionally like roads for cell movement. Cells bind to ECM components through 
transmembrane receptors on their plasma membranes. In animal cells, integrins are an 
important family of ECM receptors, which are necessary for cell adhesion during migration. 
Integrins are heterodimeric transmembrane proteins formed from association of α and β 
polypeptide chains (Berrier and Yamada 2007). There are many different combinations of 
possible α and β heterodimers, which impart binding specificity for different components of 
the ECM (Luo, Carman et al. 2007). For instance, α5β1 binds fibronectin whereas α6β1 binds 
laminin. When migrating cells adhere to the ECM, integrins link the cell cytoskeleton to 
specific ECM substrates, forming a structure called a focal adhesion. Specific integrin-ECM 
binding and focal adhesion formation initiate appropriate cellular signaling pathways to 
facilitate cell motility. As the cell moves along its substrate, new focal adhesions are 
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continuously being formed at the leading edge of the cell and released from the back of the 
cell (Ridley, Schwartz et al. 2003). Therefore, the cell may recognize different ECM 
components as suitable adhesive substrates, and the appropriate cell migration signaling 
cascades are then initiated. This process is essential during development when large-scale 
cell movements occur in a highly coordinated manner (Ridley, Schwartz et al. 2003). 
 
1.1.3. The ECM as a regulator of cell signaling 
In addition to its roles in mediating cell motility and providing structural integrity for 
tissues, the ECM is also an important regulator of cell signaling in multicellular organisms. 
heparan sulfate, a component of many proteoglycans, can bind to secreted growth factors in 
the ECM, thereby transforming the matrix into a basin for biologically active molecules. The 
association of growth factors with the ECM is important during embryogenesis, as growth 
factors can be used to establish morphogenic gradients which pattern developmental events 
(Hynes 2009). ECM proteoglycans bind to a variety of signaling molecules and growth 
factors including fibroblast growth factor (FGF), vascular endothelial growth factor (VEGF), 
and transforming growth factor-β (TGF-β) (Shi and Massague 2003; Mohammadi, Olsen et 
al. 2005). Cleavage of ECM proteins or of the GAGs associated with ECM proteoglycans 
releases these signaling factors (discussed further in sections 1.6 and 1.7), which can 
subsequently affect cell behavior, leading to changes in migration, proliferation, and survival 
(Hynes 2009).   
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1.2 Matrix Metalloproteinases  
1.2.1. Structure and function of MMPs 
Matrix metalloproteinases (MMPs) are a family of 25 secreted zinc-dependent 
endopeptidases. The primary function of MMPs is to facilitate cleavage and remodeling of 
the ECM through selective degradation of ECM components (Vu and Werb 2000).  
Traditionally, MMPs have been classified into four groups on the basis of their substrate 
specificity for particular ECM components: collagenases, gelatinases, stromelysins and 
matrilysins. As the list of MMP substrates has become longer and more complex, however, it 
is now more common to classify MMPs into two distinct groups based on their structure and 
localization: membrane-type MMPs (MT-MMPs), which are anchored to the cell surface, 
and secreted MMPs, which are soluble in the ECM (Egeblad and Werb 2002).  
Although MMP localization and substrate specificity may vary, most MMPs contain 
several conserved domains, which are essential for their structure and function. Generally, 
MMPs contain a cleaved N-terminal signal sequence used for secretion, an N-terminal 
propeptide (PRO) domain that regulates activity, a catalytic Zn2+-binding domain that 
contains the MMP catalytic site, a linker domain (also called the hinge region), and a 
hemopexin (HPX) domain that mediates interactions with target proteins (Nagase, Visse et 
al. 2006). All MMPs are synthesized as inactive proenzymes, and become activated after the 
removal of their PRO domain. The PRO domain inhibits MMP activity through interaction of 
a cysteine residue in the PRO domain with the zinc moiety in the MMP catalytic site 
(Nagase, Visse et al. 2006). Most secreted MMPs are activated in the ECM by other active 
MMPs or serine proteases; whereas, the MT-MMPs are cleaved intracellularly in the Golgi 
by furin-like serine proteases and inserted into the plasma membrane in their active form 
(Sternlicht and Werb 2001).  
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1.2.2. Membrane-type MMPs  
Membrane-type MMPs are a particularly unique class of metalloproteinase. Unlike 
secreted MMPs which are activated extracellularly and may diffuse freely throughout the 
ECM, MT-MMPs are activated intracellularly and immobilized in the plasma membrane, 
thus, the activites of the MT-MMPs are limited to the surface of the cells that produced them 
(Seiki 2002). There are six MT-MMPs that have been identified: MT4- and MT6-MMP are 
anchored to the cell surface via a glycosylphosphatidylinositol (GPI) anchor; whereas, MT1-, 
MT2-, MT3- and MT5-MMP are type I transmembrane proteins, containing a single 
transmembrane domain and short cytosolic C-terminal domain (Seiki 2002). The presence of 
a C-terminal domain is distinctive to this subset of MT-MMPs and plays an important role in 
regulating cellular localization and turnover of these proteins (Wang, Ma et al. 2004).    
 
1.2.3. MT1-MMP 
Of the six MT-MMPs, MT1-MMP (also known as MMP-14) was the first identified, 
and is also the best characterized. MT1-MMP can digest a number of cell surface 
components (CD44, cadherin) and ECM proteins, including type IV collagen, and is a key 
regulator of cellular invasion in development and disease. The cytosolic C-terminal tail of 
MT1-MMP is important in regulation of invasiveness, as deletion of this domain decreased 
the invasion-promoting activity of MT1-MMP in human melanoma cells (Lehti, Valtanen et 
al. 2000). Additionally, the C-terminal domain of MT1-MMP has been linked to enhanced 
cell migration by facilitating localization of MT1-MMP to invadopodia, and has also been 
linked  to internalization and turnover of the enzyme with respect to its presence on the 
membrane, highlighting the importance of this domain in regulating MT1-MMP function 
(Nakahara, Howard et al. 1997; Jiang, Lehti et al. 2001; Uekita, Itoh et al. 2001). As well as 
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cleaving known ECM substrates, MT1-MMP is involved in the activation of pro-MMP-2 
(see section 1.2.4.), which further augments the migratory potential of MT1-MMP expressing 
cells (Itoh, Takamura et al. 2001). Upregulation of MT1-MMP is often associated with 
pathological conditions including cancer, partly due to its direct role in facilitating cell 
migration and invasion, and partly due to its role in activating pro-MMP-2, which is a very 
robust ECM protease. Not surprisingly, MT1-MMP also plays an important role in 
development.  Of the many MMP knockout mouse models, only the MT1-MMP null mutant 
is lethal, resulting in death by 3 weeks of age due to severe skeletal and vascularization 
defects (Zhou, Apte et al. 2000). 
 
1.2.4. The gelatinases 
The gelatinases MMP-2 (gelatinase A) and MMP-9 (gelatinase B) are considered two 
potent ECM proteases primarily because of their ability to cleave type IV collagen, which is 
an abundant component of BMs (Khasigov, Podobed et al. 2003). MMP-2 and -9 have 
important functional roles in vivo, particularly during development, as cleavage of BM 
components is important in facilitating cell migration and differentiation (Werb, Ashkenas et 
al. 1996; Carinato, Walter et al. 2000). During mouse development, MMP-9 expression is 
detected in the liver, the endochondral plates of developing bone, neural cells, and 
developing respiratory structures including the bronchial epithelium of the lungs and the 
developing alveoli (Canete-Soler, Gui et al. 1995). In contrast, MMP-2 expression is detected 
mainly in mesenchymal tissues and organs such as kidney and lung (Reponen, Sahlberg et al. 
1992). Further studies using avian embryos have shown that MMP-2 expression is required in 
neural crest cells to facilitate an epithelial to mesenchymal transition (EMT), where the 
neural crest cells detach from the neural epithelium and migrate away from the neural tube 
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(Duong and Erickson 2004). As mentioned above, MT1-MMP is involved in direct activation 
of pro-MMP-2. Active MMP-2 can in turn cleave and activate pro-MMP-9, thus, the 
gelatinases function as part of a powerful axis that controls degradation of ECM components 
(Toth, Chvyrkova et al. 2003). As such, upregulation in the activities of these MMPs are 
frequently associated with disease. MMP-2 and -9 play a significant role in cancer metastasis 
and facilitate EMT through cleavage of the BM, which leads to cell invasion (Khasigov, 
Podobed et al. 2003). Accordingly, MMP activity must be tightly regulated in a controlled 
manner to maintain normal tissue homeostasis both during development and in adults.  
 
1.3 Tissue Inhibitors of Metalloproteinases   
The tissue inhibitors of metalloproteinases (TIMPs) are endogenous MMP inhibitors, 
which play important roles in regulating MMP activity in vivo. In vertebrates, four TIMPs 
have been identified (TIMP 1-4). TIMP orthologs are found in many species throughout the 
animal kingdom including worms and insects, indicating the importance of this ancient 
protein family (Murphy 2011). Together, the four vertebrate TIMPs have the ability to inhibit 
all known MMPs (Visse and Nagase 2003). As TIMPs exhibit functional redundancy, 
orthologs of each TIMP are not expressed in all vertebrates; however, mammals express all 
four TIMPs (Murphy 2011).   
TIMP genes are regulated at the transcriptional level through cytokine and growth 
factor signaling, and the expression patterns of the individual TIMPs are variable. While 
TIMP-2 tends to be constitutively expressed, the other TIMPs show more tissue-specific 
expression patterns (Murphy 2011). Most notably, TIMP-1 is highly expressed in 
reproductive organs and the central nervous system, particularly in regions of neuronal 
plasticity such as the hippocampus and cerebellum. In contrast, TIMP-3 expression is often 
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associated with the BMs of the eye and kidney (Murphy 2011). Although there is functional 
redundancy in many of the MMP-inhibitory activities of the four TIMPs, there are subtle 
differences in their inhibitory abilities. For instance, TIMP-3 is unique with respect to the 
other TIMPs due to its ability to strongly inhibit members of the A Disintegrin and 
Metalloproteinase (ADAM) family proteases, including ADAM-17 (also known as TACE; 
Tumor necrosis factor-α converting enzyme) (Amour, Slocombe et al. 1998).  
 
1.3.1. TIMP domain structure and function 
TIMPs are small secreted proteins found within the ECM, where after removal of an 
N-terminal signal sequence, the mature TIMP proteins generally consist of between 184 – 
194 amino acids. The individual TIMP family members each have similar tertiary structure, 
and can be divided into distinct N- and C-terminal domains (Nagase, Visse et al. 2006). As a 
group, the mammalian TIMPs share 35-50% sequence similarity at the amino acid level, and 
there are specific structural features that are highly conserved amongst all TIMPs.  Most 
importantly, all TIMPs contain 12 conserved cysteine resides which form 6 intramolecular 
disulfide bonds (Murate and Hayakawa 1999).  The positions of the 12 cysteine residues and 
the subsequent formation of the disulfide bonds are crucial for the proper folding of all TIMP 
proteins into a looped structure, which delineates and stabilizes the conformations of the N- 
and C-terminal domains. The first 6 cysteine residues form 3 loops that comprise the TIMP 
N-terminal domains. Likewise, the latter 6 cysteine residues form 3 C-terminal domain loops 
(Figure 1.1) (Murate and Hayakawa 1999). The two TIMP domains are structurally and 
functionally distinct, and have been shown to fold and function independently in vitro (Brew 
and Nagase 2010; Bahudhanapati, Zhang et al. 2011). 
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The primary role of TIMPs is to inhibit MMP enzymatic activity, thereby regulating 
cleavage and degradation of ECM components. The TIMP N-terminal domains are 
responsible for direct inhibition of MMP activity via binding to the MMP active site in a 1:1 
manner, chelating the Zn2+ ion in the MMP active site, and effectively blocking MMP 
catalytic activity (Nagase, Visse et al. 2006). Although it was originally believed that the sole 
function of TIMPs was to attenuate the action of MMPs, it is now known that the TIMP C-
terminal domains have MMP-independent functions and can influence cell behavior through 
direct regulation of a number of cell signaling pathways (Chirco, Liu et al. 2006). The C-
terminal domains of the various TIMPs have been linked to cell growth, migration, and 
apoptosis pathways (Guedez, Stetler-Stevenson et al. 1998; Wang, Yamashita et al. 2002; 
Oh, Seo et al. 2004). To date, however, much of the work characterizing TIMP domain 
function has been carried out in vitro. Although some cell surface binding partners and 
signaling events associated with the TIMP C-terminal domains have been identified, 
activation of specific signaling pathways in vitro varies with TIMP and cell type (discussed 
further in section 1.6.2.) (Bourboulia and Stetler-Stevenson 2010). Currently, comparatively 
little research has been done characterizing TIMP domain function in vivo. 
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Figure 1.1. General schematic secondary structure of TIMP proteins. Mature TIMP 
proteins contain 12 conserved cysteines (numbered in blue). The 6 N-terminal cysteine 
residues (red) form 3 disulfide bonds, which result in 3 loops that comprise the N-terminal 
domains (dashed line; loop 1-3). The 6 C-terminal cysteine residues (purple) form 3 disulfide 
bonds, which result in 3 loops that comprise the C-terminal domains (dotted line; loop 4-6). 
The arrow indicates the short boundary region between N- and C-terminal domains. Based on 
(Murate and Hayakawa 1999). 
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1.4 Reversion-inducing Cysteine-rich Protein with Kazal Motifs  
In addition to TIMPs, REversion-inducing Cysteine-rich protein with Kazal motifs 
(RECK) is another important regulator of MMP activity in both development and disease. 
RECK is a cell surface MMP inhibitor that contains three serine protease inhibitor-like 
domains (termed Kazal motifs) and is bound to the plasma membrane via a GPI anchor at its 
carboxy terminus (Takahashi, Sheng et al. 1998).  The RECK gene was first isolated from a 
ras-transformed mouse fibroblast cell line (NIH3T3 cells). Due to its MMP-inhibitory 
activity, RECK has since been identified as an important tumor suppressor protein with anti-
invasive properties (Takahashi, Sheng et al. 1998). While RECK is expressed in many normal 
adult tissues, its expression is often undetectable in tumor cell lines. Moreover, RECK has 
been shown to be down-regulated in response to various oncogenes, including ras 
(Takahashi, Sheng et al. 1998; Sasahara, Takahashi et al. 1999).  
In addition to its role as a tumor suppressor, RECK is also important in regulating 
developmental events. During development, RECK expression is high in cells that make up 
the developing blood vessels and low in the surrounding tissues (Oh, Takahashi et al. 2001). 
Studies using mice have shown that RECK-deficient embryos have impaired formation of the 
vasculature (Oh, Takahashi et al. 2001).  Vascular development is highly reliant on cell 
migration and ECM remodeling mediated by active MMPs, however, excessive MMP 
activity can also be detrimental during this process, and thus, must be tightly controlled. As 
RECK is known to be a good inhibitor of potent MMPs including MMP-2, MMP-9 and 
MT1-MMP, inhibition of MMP activity by RECK is essential during vascularization 
(Takahashi, Sheng et al. 1998; Oh, Takahashi et al. 2001). Taken together, the action of 
MMP inhibitors like RECK and TIMPs balanced with the action of active MMPs is 
extremely important in regulating ECM remodeling events in development and in disease.  
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1.5 Regulation of the ECM Proteolytic Network 
To achieve and maintain homeostasis, the activities of MMPs, TIMPs, and RECK 
must be tightly controlled and constantly adjusted.  In combination with the balance between 
secreted MMP and TIMP levels in the ECM, regulation of cell surface proteases and 
inhibitors like MT1-MMP and RECK, together play important roles in controlling the 
function, migration, and invasiveness of cells (Bourboulia and Stetler-Stevenson 2010). In 
addition to maintaining the appropriate balance between the activities of ECM proteases and 
inhibitors, the individual contributions of the TIMP N- and C-terminal domains must also be 
balanced with respect to the relative abundance of their appropriate binding partners in the 
ECM and on the cell surface. Whereas the TIMP N-terminal domains bind to MMPs in the 
ECM, the C-terminal domains can also influence cell behavior by signaling through cell 
surface receptors. As we learn more about the ECM and the proteins within it, it is evident 
that regulation of the ECM proteolytic network is exceedingly complex. As a result, 
increasing research has focused on the relative levels of, and interactions between, 
extracellular and cell surface proteins. It is now clear that MMPs and TIMPs are not only 
important in regulating ECM turnover, but that MMP non-proteolytic and TIMP non-
inhibitory domains also play important roles in regulating ECM dynamics and cell behavior. 
In this section I will discuss some of the complex interactions between MMPs and TIMPs, 
and the ways in which TIMPs can regulate ECM dynamics, aside from direct inhibition of 
MMP activity. 
1.5.1. TIMP-2 mediated activation of pro-MMP-2 
TIMPs are important multifunctional proteins that can influence cell behavior, 
through several different mechanisms. As previously mentioned, TIMP N-terminal domains 
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are known to inhibit MMP activity, and TIMP C-terminal domains have been associated with 
various cell surface receptors and signaling pathways, however, TIMPs can also interact with 
cell surface MMPs or receptors to modulate the expression and activity of other proteins. An 
important example of such an interaction is the association between MT1-MMP, TIMP-2, 
and pro-MMP-2 (Seiki 2002). Active MT1-MMP on the cell surface (primarily on migratory 
cells), can bind to pro-MMP-2 and TIMP-2 in a complex that ultimately results in the 
activation of pro-MMP-2. In this complex, two molecules of MT1-MMP are required in 
close proximity on the cell surface (Itoh, Takamura et al. 2001). One molecule of MT1-MMP 
serves as a receptor for TIMP-2 and pro-MMP-2. The C-terminal domain of TIMP-2 binds to 
the HPX domain of pro-MMP-2, while its N-terminal domain binds to and inhibits the 
catalytic domain of MT1-MMP. Thus, TIMP-2 is required for the appropriate positioning of 
pro-MMP-2, and serves as an adaptor between MT1-MMP and pro-MMP-2 in this complex. 
A second MT1-MMP then cleaves the PRO domain of the appropriately positioned pro-
MMP-2 resulting in its activation (Figure 1.2) (Itoh, Takamura et al. 2001). Relative 
stoichiometry between the levels of MMPs, TIMPs, and cell surface receptors may have an 
important impact on the formation of this complex. For instance, low levels of TIMP-2 
facilitate activation of pro-MMP-2, however, higher levels of TIMP-2 saturate and inhibit 
available MT1-MMP receptors, thereby preventing pro-MMP-2 activation (Romi, Helgeland 
et al. 2012). As MT1-MMP/TIMP-2 mediated activation of pro-MMP-2 is known to 
dramatically increase the migratory and invasive potential of cells, the stoichiometry needed 
for the proper formation of this complex is important during both development and cancer 
progression (Itoh, Takamura et al. 2001).  
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1.5.2. Regulation of pro-MMP-9 in the ECM 
Activation of pro-MMP-9 is another important determinant in regulating cell 
migration and invasion. Similar to pro-MMP-2 activation, extracellular cleavage of pro-
MMP-9 involves complex interactions between a variety of ECM and cell surface proteins. 
In cancer cells, pro-MMP-9 activation contributes to an invasive phenotype, and pro-MMP-9 
is activated by MMP-2. The cell surface protein CD44 acts as a binding partner to position 
pro-MMP-9 for activation. CD44 and pro-MMP-9 co-localize to invadopodia where active 
MMP-2 can subsequently cleave and activate pro-MMP-9 (Figure 1.2) (Bourguignon, Gunja-
Smith et al. 1998; Murphy, Stanton et al. 1999).  As MT1-MMP activates pro-MMP-2, MT1-
MMP, therefore, also plays an important role in facilitating the downstream activation of pro-
MMP-9.  
Additionally, pro-MMP-9 is known to form a complex with TIMP-1 in the ECM 
(Goldberg, Strongin et al. 1992). This interaction occurs through the C-terminal domain of 
TIMP-1, where the N-terminal domain remains available for MMP inhibition (Itoh and 
Nagase 1995). Intracellular co-localization of TIMP-1 with pro-MMP-9 has also been 
detected in the Golgi, and many cells secrete pro-MMP-9 and TIMP-1 together (Roderfeld, 
Graf et al. 2007). Although the functional significance of this complex remains unknown, it 
has been suggested that association of pro-MMP-9 with TIMP-1 may be required for 
stabilization of the zymogen (inactive pro-enzyme) and regulation of proteolytic activity. 
Collectively, these studies with MMP-2 and -9 highlight the complexity of the interactions 
between various ECM molecules as well as the importance of the non-inhibitory TIMP 
domains in regulating the ECM proteolytic network. 
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1.5.3. TIMP-2 mediated upregulation of RECK 
In addition to their direct roles in regulating the activities of ECM proteins, TIMPs 
may also influence the proteolytic network indirectly through C-terminal domain-mediated 
activation of cell signaling pathways. TIMP-2 is perhaps the most well studied member of 
the TIMP family, and its MMP-independent functions have been well characterized, at least 
in vitro. In human endothelial cells, TIMP-2 has been linked to a specific signaling pathway, 
which ultimately results in upregulation in RECK expression and decreased cell migration 
(Oh, Seo et al. 2004). A series of elegant experiments have demonstrated that TIMP-2-
mediated upregulation in RECK expression is independent of its N-terminal MMP-inhibitory 
domain, and occurs through binding of the TIMP-2 C-terminal domain to α3β1 integrin 
receptors on the cell surface (Seo, Li et al. 2003; Seo, Li et al. 2006). Along with co-
immunoprecipitation of α3β1 integrins using TIMP-2 antibodies, competitive binding studies 
using antibodies that block the α3 and β1 integrin subunits have shown that TIMP-2 binding 
is specific to α3β1 integrin receptors on human microvascular endothelial cells (Seo, Li et al. 
2003). By the addition of a single alanine residue to the N-terminal domain of TIMP-2 
(ALA+TIMP-2), the N-terminal domain MMP-inhibitory activity is disrupted, leaving only a 
functional C-terminal domain (Wingfield, Sax et al. 1999). Both TIMP-2 and ALA+TIMP-2 
were shown to bind to α3β1 integrins leading to upregulation in RECK RNA and RECK 
protein (Figure 1.2) (Oh, Diaz et al. 2006; Seo, Li et al. 2006). As RECK is a cell surface 
inhibitor of MT1-MMP, MMP-2, and MMP-9, increased RECK expression resulted in 
decreased endothelial cell migration (Oh, Seo et al. 2004; Oh, Diaz et al. 2006).   
Thus, in addition to direct inhibition of MMP activity by its N-terminal domain, 
TIMP-2 may function to indirectly inhibit MMP activity through C-terminal domain-
mediated upregulation of RECK. With the added contradictory ability of TIMP-2 to activate 
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pro-MMP-2 in association with MT1-MMP, regulation of this important ECM molecule is 
essential for maintiaing homeostasis in the ECM. Given the complexity involved in the 
regulation of TIMP-2 activities alone, when examined in concert with the varied activities of 
the other TIMPs and MMPs, it is evident that disruptions to the intricate dynamics of the 
ECM proteolytic network may have negative consequences for the organism as a whole.  
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Figure 1.2. Cell surface regulation of the ECM proteolytic network. From left to right, 
pro-MMP-9 binds CD44 on the cell membrane where it is activated by MMP-2. TIMP-2 
complexes with MT1-MMP and pro-MMP-2 to mediate cleavage and activation of pro-
MMP-2 by a second molecule of MT1-MMP. The TIMP-2 C-terminal domain binds to α3β1 
integrins on the cell surface leading to upregulation in the cell surface MMP inhibitor, 
RECK. RECK subsequently inhibits the activity of MT1-MMP, MMP-2, and MMP-9. 
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1.6 Functions of the ECM Proteolytic Network in Cancer     
1.6.1. The role of MMPs in cancer and metastasis 
For many years it has been known that upregulation of MMP levels and activities are 
detrimental to normal tissue function. Although MMPs are highly active during development 
when many cell migration and ECM remodeling events occur, their activities must still be 
tightly regulated at this time. In contrast, MMP expression is limited in most adult tissues and 
elevated MMP activity is associated mainly with controlled remodeling events such as 
wound healing (Ma, Tarnuzzer et al. 1999). In adult tissues, increases in MMP activity are 
associated with pathological conditions, most commonly cancer.  
MMPs have been implicated as positive regulators of cancer progression from the 
early stages of tumor growth to later stages of invasion and metastasis (Mandal, Mandal et al. 
2003). In early stages, cleavage of the ECM or BM components by MMPs contributes to the 
formation of a microenvironment that promotes tumorigenesis. The tumor microenvironment 
is a combination of tumor cells, stromal cells, growth factors and ECM constituents. Within 
the past decade, the tumor microenvironment has become recognized as an important 
regulator of tumor behavior (Bhowmick, Neilson et al. 2004; Littlepage, Egeblad et al. 2005). 
MMPs are secreted by tumor cells and tumor-associated fibroblasts, and the roles of active 
MMPs within the microenvironment are varied. Through direct cleavage of the structural 
ECM molecules collagen IV and laminin 5, MMPs expose cryptic sites on these proteins that 
foster tumor cell growth and angiogenesis (Xu, Rodriguez et al. 2001). Additionally, many 
cytokines and growth factors are sequestered within the ECM. Degradation of the ECM may 
facilitate release of growth factors, and further direct cleavage of latent growth factors by 
MMPs may facilitate their activation. Release of and/or activation of growth factors in the 
ECM significantly contributes to tumor progression by enhancing tumor cell growth, 
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angiogenesis, and tumor cell migration (Bourboulia and Stetler-Stevenson 2010). For 
instance, MMP-9 can release VEGF from the ECM, leading to increased angiogenesis 
(Bergers, Brekken et al. 2000). Similarly, insulin-like growth factors (IGFs) and TGF-β are 
important targets of MMP activity in tumors. MMPs cleave IGF binding proteins, permitting 
release of IGFs and binding of IGFs to their receptors, which results in enhanced tumor cell 
growth (Bergers, Brekken et al. 2000). Additionally, MMP-2 and -9 specifically, can release 
and activate fibronectin-bound TGF-β, which induces EMT and promotes tumor cell 
proliferation (Yu and Stamenkovic 2000).  
As well as triggering tumorigenesis, MMPs also contribute to later stages of tumor 
progression by facilitating cell migration and invasion, which are important factors that 
contribute to metastasis. This can occur through targeted cleavage of BM or ECM 
components, or by cleavage of cell-cell adhesion molecules. For instance, degradation of the 
strcutural ECM molecule laminin 5 by MT1-MMP leads directly to tumor cell migration; 
whereas, cleavage of membrane-bound E-cadherin by MMP-3 (stromelysin-1) and MMP-7 
(matrilysin) results in disruption of cell contacts leading to cell dissociation, which promotes 
invasion (Koshikawa, Giannelli et al. 2000; Noe, Fingleton et al. 2001). 
In summary, MMPs can contribute to cancer progression through many mechanisms, 
such as cytokine release or activation, which are not necessarily strictly related to proteolytic 
cleavage of ECM structural molecules. Additionally, MMPs positively regulate processes 
including tumor cell growth, angiogenesis, migration, and invasion, demonstrating the 
significance of these molecules in regulating the tumor microenvironment. Given the many 
roles of MMPs in cancer, it is evident that regulation of MMP activity is critical for 
prevention of disease and for  maintenance of normal tissue integrity.  
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1.6.2. The role of TIMPs in cancer 
Taking into consideration the importance of MMP activity in tumor progression, 
some anti-cancer therapies have focused on sequestering MMP activity as a means of 
treatment. As all four TIMPs are naturally occurring MMP inhibitors, it was originally 
thought that TIMPs might act as an intrinsic guard against tumor progression (Stetler-
Stevenson 2008). Accordingly, synthetic MMP inhibitors were designed to mimic the N-
terminal MMP-inhibitory activities of TIMPs, however, these drugs failed as anti-cancer 
therapies in clinical trials (Brown 1998; Coussens, Fingleton et al. 2002). It is now broadly 
acknowledged that while TIMPs do have some anti-tumorigenic properties, TIMPs play a 
dual role in the regulation of tumorigenesis. Though TIMPs were originally characterized 
based on their ability to inhibit MMP activity, the importance of the additional biological 
activities mediated by the TIMP C-terminal domains is now widely recognized. Through 
their C-terminal domains, TIMPs can influence a variety of cell signaling pathways including 
cell growth, migration, and apoptosis. These MMP-independent functions may have 
significant implications for the progression and treatment of disease (Stetler-Stevenson 
2008). 
Both TIMP-1 and -2 have been shown to have cell growth promoting activity in a 
variety of cancer cell lines (Stetler-Stevenson, 2008). The cell growth promoting abilities of 
TIMP-1 and -2 were demonstrated through their ability to induce increased uptake of [3H] 
thymidine in several tumorigenic cell lines. This activity is specific to the TIMP C-terminal 
domains, as reductive alkylation, which renders TIMP N-terminal domains devoid of MMP-
inhibitory activity, did not abolish the growth promoting abilities of TIMP-1 and -2 
(Hayakawa, Yamashita et al. 1992; Hayakawa, Yamashita et al. 1994).  It has been suggested 
that TIMP-1 and -2 may enhance cell growth through ras-dependent pathways, as research 
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using an osteosarcoma cell line showed that both TIMP-1 and -2 increased the levels of GTP-
bound (active) ras in a dose-dependent manner (Wang, Yamashita et al. 2002). A more recent 
study showed that TIMP-2 binding to MT1-MMP on the surface of MCF-7 breast cancer 
cells might stimulate tumor cell growth through activation of the mitogen-activated protein 
kinase (MAPK) pathway (D'Alessio, Ferrari et al. 2008). This study also demonstrated that 
the TIMP-2 cell growth promoting activities are dependent on its C-terminal cell signaling 
domain, as both TIMP-2 and ALA+TIMP-2 were able to activate MAPK (Figure 1.3). 
Moreover, this work implicates an important role for the C-terminal domain of MT1-MMP in 
cell signaling, as MT1-MMP mutants devoid of a cytosolic domain were unable to transmit 
the signal (D'Alessio, Ferrari et al. 2008). 
Although specific cell growth promoting pathways for TIMP-1 have not been as well 
characterized, TIMP-1 has also been linked to inhibition of apoptosis in various cancer cell 
lines. In Burkitt’s lymphoma cell lines, both TIMP-1 and alkylated TIMP-1 devoid of MMP-
inhibitory activity suppressed apoptosis. TIMP-1 was associated with reduced activity of 
caspase-3 as well as an increase in the survival factor Bcl-XL (Guedez, Stetler-Stevenson et 
al. 1998). In MCF10A human breast epithelial cells, TIMP-1 has also been shown to 
suppress anoikis, which is a form of programmed cell death initiated by loss of cell adhesion 
(Li, Fridman et al. 1999). More recent research has identified CD63, a member of the 
tetraspanin family, as a cell surface binding partner for TIMP-1 in MCF10A cells. TIMP-1 
has been shown to form a complex with CD63 and β1 integrin on the cell surface (Figure 
1.3). Formation of this complex mediates the anti-apoptotic properties of TIMP-1, as down-
regulation of CD63 using short-hairpin RNA restored the cell’s ability to undergo apoptosis 
(Berditchevski and Odintsova 1999; Jung, Liu et al. 2006). TIMP-3 has also been associated 
apoptosis, and has been linked to both induction and inhibition of apoptosis, depending on 
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the model system used. Unlike TIMP-1, however, there is currently limited data to support 
the notion that TIMP-3 may directly participate in cell signaling. Rather, it has been 
suggested that TIMP-3 may indirectly influence cell behavior through modulation of MMP 
and ADAM activity, which in turn can alter the availablity of signaling molecules within the 
ECM (reviewed in Stetler-Stevenson, 2008). Both the cell growth promoting and anti-
apoptotic activities of TIMPs demonstrate that TIMPs are multifunctional proteins that may 
contribute to cancer progression through many different mechanisms. 
In contrast to TIMP-1, which is upregulated in many cancers and has generally been 
associated with negative prognosis, TIMP-2 has varying effects on tumor progression and 
may also exhibit anti-tumorigenic properties through its C-terminal cell signaling domain in 
addition to its MMP-inhibitory activities (reviewed in Stetler-Stevson, 2008). This is 
highlighted through research by Oh et al. (2004), which showed that TIMP-2 and 
ALA+TIMP-2 binding to α3β1 integrins on the surface of human microvascular endothelial 
cells initiated a signaling cascade that resulted in increased expression of RECK and 
subsequently decreased cell migration (Figure 1.3, and discussed in section 1.5.3.). 
Interestingly, association of TIMP-2 with α3β1 integrins also resulted in cell growth arrest in 
G1 phase of the cell cycle through increased de novo expression of the cyclin-dependent 
kinase inhibitor p27Kip1 (Figure 1.3) (Seo, Li et al. 2006). Thus, TIMP-2 may act to either 
promote or inhibit cell growth in different cell lines in vitro. 
Taken together, these studies highlight the fact that TIMP activities are both cell type 
and context dependent. Added to the complexity, TIMP function also depends on the relative 
stoichiometry of matrix and signaling molecules within the ECM and on the cell surface. For 
instance, the presence of MMP-9 may alter the signaling activity of TIMP-1 through CD63 
receptors. MMP-9 can compete with CD63 for binding of TIMP-1, thus reducing or 
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abolishing the anti-apoptotic activity of TIMP-1 in complex with CD63 on the cell surface 
(Chirco, Liu et al. 2006). As most of the research characterizing TIMP domain function has 
been carried out in vitro under controlled conditions, where many ECM interactions are 
limited, the roles of the TIMP C-terminal domains in cell signaling seem to vary with cell 
type. Accordingly, there is a need to further examine the roles of TIMPs in vivo, where the 
complexity of the ECM in the whole organism may influence TIMP function, particularly 
with respect to the availability of the TIMP C-terminal domains to participate in cell 
signaling events.  
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Figure 1.3. Regulation of cell signaling by TIMP-1 and TIMP-2 at the cell surface. From 
left to right, TIMP-1 binds to β1 integrin and CD63 through its C-terminal domain to initiate 
a signaling cascade that results in inhibition of apoptosis. The C-terminal domain of TIMP-2 
binds to MT1-MMP to initiate MAPK signaling. The TIMP-2 C-terminal domain binds to 
α3β1 integrins leading to p27Kip1-mediated inhibition of cell growth and upregulation of the 
membrane bound MMP inhibitor RECK. 
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1.7 The role of the ECM Proteolytic Network in Regulating Development 
While the MMP/TIMP balance must be tightly regulated in normal adult tissues to 
prevent tumorigenesis, both MMPs and their inhibitors are highly expressed during 
development to permit ECM proteolysis and remodeling. Indeed, many of the same processes 
that are upregulated during tumor progression are also required for the progression of normal 
development. Cell migration, cell invasion, and angiogenesis are important developmental 
processes required for tissue morphogenesis and organ formation. Consequently, the action 
of MMPs and their inhibitors, TIMPs and RECK, are also important regulators of 
development. 
1.7.1. Cell migration and tissue remodeling in development 
Cell migration is vital during embryonic development and permits the cellular 
rearrangements and cell signaling processes that are required for many important 
developmental events, the earliest of which are gastrulation and germ layer induction. 
Migration is largely mediated by the activity of MMPs, which cleave ECM components, 
releasing cytokines and clearing a space in the ECM through which cells can move. For 
example, one process that is absolutely dependent on cell motility is the migration of the 
neural crest cells away from the neural tube to form the sensory ganglia (Prendergast, Linbo 
et al. 2012). Although MMPs are required during this process, MMP activity must also be 
tightly regulated to prevent aberrant development. RECK has been implicated as an 
important regulator of neural crest cell migration as studies examining early zebrafish 
development showed that mutation in the RECK gene inhibited proper formation of the 
dorsal root gangia (Prendergast, Linbo et al. 2012).  
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Cell migration is also essential during long bone development, at which time 
osteoclasts must invade the cartilage primordium in order to begin the process of 
endochondral ossification. Osteoclast invasiveness has been shown to rely on high expression 
and activity of MMP-9, where cell migration into the cartilage matrix is limited by MMP 
inhibitors (Blavier and Delaisse 1995). MT1-MMP may also play an important role in 
regulating bone development as MT1-MMP knockout mice display severe skeletal defects 
including craniofacial abnormalities and dwarfism (Holmbeck, Bianco et al. 1999). 
Additionally, the MT1-MMP null mouse has more acute developmental defects compared to 
other MMP knockout mouse models, indicating the significance of this multifunctional 
protein in regulating developmental events (Zhou, Apte et al. 2000). 
 Proper development of the central nervous system (CNS) is another process that is 
highly reliant on cell migration and invasion. During CNS development, neurons must extend 
long axonal extensions to form synaptic connections, and MMP-9 has been shown to be an 
important regulator of neuronal outgrowth (Chambaut-Guerin, Herigault et al. 2000). 
Aberrant regulation of MMP-9 during neural development can lead to CNS defects and 
improper synapse formation; therefore, it is not surprising that TIMPs have been associated 
with tight regulation of MMP activity during this time. TIMP-1 knockout mice exhibit 
significant neuronal impairment, and have difficulty forming and retaining reward 
associations compared with wild-type mice (Chaillan, Rivera et al. 2006). Similarly, TIMP-2 
null mice exhibit neurological abnormalities and motor dysfunction, highlighting the 
importance of maintaining the balance between MMP and TIMP activity during development 
(Jaworski, Soloway et al. 2006). 
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1.7.2. ECM-dependent regulation of angiogenesis 
 One of the most well studied developmental processes is angiogenesis, the formation 
and branching of blood vessels that allows for complete vascularization of the animal. The 
requirement for proper blood vessel formation during embryonic development, coupled with 
the role of this process in facilitating tumor progression, has made angiogenesis a hot topic of 
research in the last several decades. Angiogenesis is highly dependent on the action of MMPs 
and their inhibitors, TIMPs and RECK. During angiogenesis, cells must first migrate into the 
surrounding ECM. Branching morphogenesis follows, which is an organized process that is 
very reliant on MMP activity. MMPs are needed to clear space in the ECM, which permits a 
column of endothelial cells to advance forward and migrate into the extracellular space, 
forming a new blood vessel and eventually leading to vascularization of the tissue (Stetler-
Stevenson 1999). In addition to cell motility, the formation of tubular structures and branch 
points during angiogenesis also requires changes in cell shape, proliferation, and the 
formation of new cell contacts (Vu and Werb 2000). Following proliferation and migration 
into the ECM, endothelial cells tightly adhere to one another and to the BM, and form a 
lumen for the new blood vessel (Stetler-Stevenson 1999). This process is largely driven by 
cell interactions with the ECM and requires tightly regulated ECM remodeling events. 
 In particular, MMP-2, MMP-9 and MT1-MMP have been associated with 
angiogenesis. Although MMP activity is required for blood vessel development, the action of 
TIMPs and RECK must be precisely regulated during this process as well (Handsley and 
Edwards 2005). While the N-terminal domain of TIMP-2 directly inhibits MMPs, the TIMP-
2 C-terminal domain also has demonstrated anti-angiogenic activity in vivo. As previously 
mentioned, the carboxy terminus of TIMP-2 can bind α3β1 integrins leading to reduced 
proliferation of endothelial cells (Feldman, Stetler-Stevenson et al. 2004). Additionally, 
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association of TIMP-2 with α3β1 integrins led to enhanced expression of RECK, which 
subsequently decreased endothelial cell migration through inhibition of MMP-2, -9, and 
MT1-MMP (Oh, Seo et al. 2004). 
 Just as excessive inhibition of MMP activity can have negative effects on 
angiogenesis, too little inhibition of MMP activity is also associated with defects in 
vascularization. RECK deficient embryos die at embryonic day 10.5 as a result of arrested 
vascular development (Oh, Takahashi et al. 2001). Histological examination of these 
embryos showed that the blood vessels were abnormally large and deformed, demonstrating 
the requirement for MMP inhibitors in mediating MMP activity during angiogenesis 
(Chandana, Maeda et al. 2010). Thus, these studies again emphasize the requirement for 
balance between MMP, TIMP and RECK activity in the ECM.   
 
1.7.3. ECM-dependent regulation of cell signaling in development 
In addition to the direct roles of MMPs and their inhibitors in regulating ECM 
remodeling during development, the activities of MMPs, TIMPs and RECK can also 
contribute to important ECM associated signaling events, which may help to pattern 
development. MMP-mediated release of growth factors from the ECM may be important in 
initiating developmental processes. MMP-1 and MMP-3 are known to release bound FGF 
from the ECM, whereas MMP-2, -3 and -7 are involved in the release of TGF-β (Whitelock, 
Murdoch et al. 1996; Imai, Hiramatsu et al. 1997). As FGF plays important roles in 
chondrocyte differentiation and proliferation, its release from the ECM may contribute to 
cartilage development. Similarly, TGF-β signaling is involved in branching morphogenesis; 
therefore, MMPs may indirectly play a role in regulating these processes through release of 
growth factors from the ECM (Vu and Werb 2000). 
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Given the multiple roles of the TIMP C-terminal domains in regulating cell motility, 
proliferation, and apoptosis pathways in vitro, it is evident that TIMPs may also have 
important functions in development aside from their direct roles in mediating ECM turnover. 
Although there is limited research that has investigated the precise roles of TIMPs in 
mediating cell signaling in vivo, we can infer the significance of these molecules in 
regulating developmental signaling events based on the numerous in vitro studies that have 
been performed. Currently, a large amount of our knowledge regarding MMP/TIMP function 
in vivo is based on correlation with their expression patterns in development, as well as their 
known activities during pathogenesis (Vu and Werb 2000). In particular, further research is 
needed to investigate TIMP domain function in vivo. Our understanding of these proteins as 
MMP inhibitors has been confounded by the more variable roles of their C-terminal domains 
in cell signaling, which currently have only been examined in vitro. As MMPs and TIMPs 
are both expressed and tightly regulated during development, when ECM remodeling is high, 
a good in vivo approach is to use a developmental model system to examine MMP/TIMP 
function. 
 
1.8 Animal Model 
The organism used as an animal model in this research is Xenopus laevis, commonly 
known as the African clawed frog. Xenopus laevis has been an important model organism in 
the field of developmental biology since the 1950’s and remains a prominent model organism 
in the developmental field due to its numerous advantages. A single X. laevis female can 
produce hundreds of eggs in a controlled manner by injecting the hormone gonadotropin. 
Xenopus laevis eggs are fertilized externally and embryos are easily maintained and reared in 
simple salt solution at room temperature. Developmental processes are easily observed in X. 
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laevis embryos due to the large size of the embryos and their blastomeres. Development 
occurs rapidly and has been thoroughly studied in X. laevis embryos. Cell movements and 
detailed fate maps have also been well characterized. Xenopus laevis embryos have easily 
recognizable developmental stages, which are well described. Gastrulation occurs at stage 
10; neurulation begins at stage 14 and continues through to stage 20 (during which time 
neural crest cell migration is beginning), ending with closure of the neural tube; and 
organogenesis occurs from stage 28 to stage 40 (during which time angiogensis is 
beginning). Each stage has recognizable structures and is associated with specific signaling 
pathways that can be utilized to examine developmental events, such as ECM proteolysis. 
For instance, it has previously been shown that disrupting the ECM during X. laevis 
development has detrimentral effects. Ectopic expression of MT3-MMP and TIMP-3 have 
been demonstrated to lead to embryonic lethality through unknown mechanisms (Pickard and 
Damjanovski 2004; Walsh, Cooper et al. 2007). Thus, this model organism can be used to 
further examine the importance of these ECM remodeling events, and to investigate more 
precisely how disruption of proper ECM remodeling may affect development. 
 In addition, X. laevis embryos are robust, largely resilient to experimental 
manipulation, and may be grafted or injected. Embryos are able to withstand extensive 
surgical micromanipulation in vitro and heal readily. One drawback of using X. laevis 
experimentally is that embryos are not ideally suited for transgenic manipulation due to their 
pseudotetraploid genome and long generation time to reach sexual maturity (2 years). 
However, X. laevis embryos are extremely resistant to microinjection, and are able to 
translate synthetic mRNA. This technique can be used for overexpression studies, and can be  
extrememly useful in understanding developmental signaling events.  
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A great deal of our current knowledge regarding early embryonic development comes 
from studies performed using X. laevis embryos.  Xenopus laevis remains an important model 
organism in the study of developmental biology. For these reasons I chose to use X. laevis as 
my model organism for studying ECM remodeling events and cell signaling events 
associated with TIMP N- and C-terminal domains. 
1.9 Research Questions 
1.9.1. Summary 
Remodeling of the ECM is required for the development and maintenance of 
multicellular organisms. Extracellular matrix remodeling occurs primarily through the action 
of MMPs, which cleave ECM components, and their endogenous inhibitors, TIMPs and 
RECK. The delicate balance between TIMPs, RECK, and MMPs are required to mediate 
developmental processes where large-scale tissue remodeling occurs, including angiogenesis, 
neural development, bone formation, and organogenesis. Disruption in the expression or 
activities of these molecules within the ECM proteolytic network can lead to developmental 
abnormalities and death. 
TIMPs are multifunctional proteins that have additional functions aside from MMP 
inhibition. TIMPs are involved in regulating a number of cell signaling pathways, including 
cell growth, migration, and apoptosis, and this activity is mediated through the C-terminus of 
TIMP proteins, independent of their MMP-inhibitory activity (which occurs exclusively at 
the N-terminus). There is little information regarding TIMP domain function in vivo, 
however, the relative levels of MMPs and TIMPs plays a role in regulating the availability of 
TIMPs at the cell surface, and subsequently, their ability to participate in signaling events. To 
date, much of the work characterizing TIMP signaling activity has been carried out in vitro, 
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and TIMP roles in cell signaling seem to vary with the cell line examined. Accordingly, there 
is a need to examine TIMP function (particularly in cell signaling) in vivo. My research 
characterizes TIMP function in vivo, using X. laevis as a model to examine the role of the 
TIMP domains during development. Specifically, this research investigates the balance 
between TIMP MMP-inhibitory functions and TIMP roles in cell signaling during 
development, and is the first comprehensive comparison of the roles of the TIMP N- and C-
terminal domains in vivo. 
1.9.2. Hypotheses 
1) The N-terminal domain sequences of each TIMP will be more highly conserved than 
the C-terminal domains, as TIMP MMP-inhibitory activity is the common function 
of these proteins. 
2) Overexpression of TIMP N-terminal domains will all produce similar developmental 
defects resulting from increased inhibition of MMP activity, due to the fact that 
TIMPs are largely redundant in their MMP-inhibitory abilities. 
3) Overexpression of TIMP-1 and -2 C-terminal domains will produce unique 
developmental defects, resulting from specific changes in cell signaling pathways; 
whereas, the TIMP-3 C-terminal domain will have limited influence on 
development, as there is currently little research supporting a direct role for the 
TIMP-3 C-terminal domain in cell signaling. 
4) Overexpression of TIMP N-terminal domains will result in similar alterations in 
expression and activity of proteolytic molecules; whereas, overexpression of the C-
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terminal domains will have varying effects on developmental regulation of these 
molecules that is dependent (presumably) on their roles in cell signaling. 
1.9.3. Objectives  
 The goal of this research was to compare the unique functions of the N- and C-
terminal domains with those of the full-length molecule for all three known X. laevis TIMPs 
during development. TIMP-2 and -3 had previously been cloned when I began this research. 
Through database searches and analysis I have cloned TIMP-1, however, there does not 
appear to be a TIMP-4 (discussed in Chapter 5) in X. laevis. This research had the following 
objectives: 
1)  Identify and characterize Xenopus laevis TIMP-1 (Chapter 3).  
2) Perform a comparison of amino acid sequence identity for the N- and C-terminal 
domains of each TIMP to determine their evolutionary conservation (Chapter 2 and 
3). 
3) Use X. laevis TIMP-1, -2 and -3 sequences to generate TIMP-1, -2 and -3 full-length, 
N-terminal, and C-terminal domain mRNA constructs (Chapter 2 and 3). 
4) Overexpress each TIMP construct in X. laevis embryos using mRNA microinjection. 
Examine embryos for resultant morphological changes and developmental 
abnormalities, to determine how each TIMP domain may contribute to large-scale 
patterning of embryonic development (Chapter 2 and 3). 
5) Examine alterations in mRNA levels of proteolytic genes, as well as changes in MMP 
activity, following overexpression of each TIMP construct to elucidate how the 
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individual TIMP domains may contribute to the regulation of the ECM proteolytic 
network (Chapter 2 and 3). 
6) Examine embryos injected with each TIMP construct to investigate changes in levels 
of key indicators of cell signaling pathways associated with overexpression of each 
TIMP domain (Chapter 4).  
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CHAPTER 2 
 
DOMAIN SPECIFIC OVEREXPRESSION OF TIMP-2 AND TIMP-3 REVEALS MMP-
INDEPENDENT FUNCTIONS OF TIMPS DURING XENOPUS LAEVIS DEVELOPMENT 
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and Damjanovski, S. (2012). Domain specific overexpression of TIMP-2 and TIMP-3 reveals 
MMP-independent functions of TIMPs during Xenopus laevis development. Biochem Cell 
Biol 90(4): 585-595”. NRC research press Copyright Clearance Center permits reuse of 
figures, tables and excerpts from any NRC Research Press article, for any purpose that 
respects the moral rights of authors without permission. The text has been modified form the 
original manuscript to adhere to formatting guidelines for this thesis. Experiments were 
designed and carried out by M.A.N., L.A.W. assisted with embryo rearing, M.A.F. assisted 
with Western blotting, S.D. provided funding, resources, and intellectual contributions.  
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2.1 Introduction 
2.1.1. TIMP overview 
 ECM remodelling carried out by MMPs and TIMPs is important in regulating 
development in multicellular organisms, and mediates processes involving large-scale cell 
movements and rearrangements, including gastrulation, organogenesis and angiogenesis 
(Blavier and DeClerck 1997; Gomez, Alonso et al. 1997; Damjanovski, Amano et al. 2001; 
Zhang, Bai et al. 2003; Nuttall, Sampieri et al. 2004; Myers, Applegate et al. 2011). As 
discussed in Chapter 1, although TIMPs were originally characterized as endogenous MMP 
inhibitors, it is now known that TIMPs contain structurally and functionally distinct N- and 
C-terminal domains, and that the TIMP C-terminal domains may be involved in direct 
regulation of a number of signaling pathways (Murphy, Unsworth et al. 1993; Guedez, 
Stetler-Stevenson et al. 1998; Ahonen, Poukkula et al. 2003; Chirco, Liu et al. 2006; 
Vanhoutte and Heymans 2010; Kallio, Hopkins-Donaldson et al. 2011). The two TIMP 
domains are thought to have evolved separately, and both domains have the ability to fold 
and function independently (Brew and Nagase 2010). This has been demonstrated through 
expression of TIMP N-terminal domains in heterologous systems, where the N-terminal 
TIMP domains still maintain a stable native structure, and can inhibit MMPs (Bahudhanapati, 
Zhang et al. 2011). 
The four mammalian TIMPs all have a similar structure and are highly conserved at 
the amino acid level (Bode, Fernandez-Catalan et al. 1999; Murate and Hayakawa 1999). The 
highest degree of sequence similarity occurs within TIMP N-terminal domains, whereas the 
C-terminal domains are more variable (Pavloff, Staskus et al. 1992; Apte, Hayashi et al. 
1994; Bodden, Harber et al. 1994; Leco, Khokha et al. 1994; Fernandez, Butterfield et al. 
2003; Brew and Nagase 2010). As discussed in section 1.5.3., TIMP-2 is the most well 
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characterized, and in human endothelial cells has been demonstrated to bind α3β1 integrins 
through its C-terminus, leading to an upregulation in RECK, which subsequently 
downregulates MMP activity and decreases cell migration  (Oh, Seo et al. 2004; Shakibaei, 
Csaki et al. 2008). While the C-terminal domains can act MMP-independently, the N-
terminal domains of all TIMPs are involved in direct binding and inhibition of the bound 
MMP's catalytic activity.  
 
2.1.2. TIMPs and MMPs in development 
To date, most research characterizing TIMP domain function has been carried out in 
vitro, where the activation of a given cell signaling pathway is dependent on both the specific 
TIMP expressed, and the cell type it is expressed in (Stetler-Stevenson 2008; Bourboulia and 
Stetler-Stevenson 2010). Although maintaining the correct MMP/TIMP balance is essential 
for proper development, little is known regarding the relationship between TIMPs and MMPs 
during embryogenesis. TIMP-1, -2 and -3 knockout mice are viable (reviewed in Brew and 
Nagase 2010), suggesting overlapping redundancies in their functions. In contrast, while 
many MMP knockouts have been generated, only the MMP-14 (MT1-MMP) null mouse 
shows severe consequences (Zhou, Apte et al. 2000).  MMP overexpression during X. laevis 
development results in both axial defects and death shortly after gastrulation, although 
specific mechanisms are not known (Hasebe, Hartman et al. 2007; Walsh, Cooper et al. 
2007). Additionally, TIMP-3 overexpression is lethal to X. laevis during development; 
however, it is unclear whether this occurs as a result of aberrantly activated cell signaling 
pathways, or as a result of improper ECM remodelling (Pickard and Damjanovski 2004).  
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2.1.3. Summary and research questions 
At the time this research was published, only TIMP-2 and -3 had been cloned in X. 
laevis (Yang and Kurkinen 1998; Klein, Strausberg et al. 2002). Mammalian TIMP-2 has 
been well characterized in vitro and is known to be localized pericellularly and associated 
with a number of cell signaling pathways (Stetler-Stevenson 2008). In contrast, TIMP-3 
interacts with sulphated GAGs and is sequestered in the ECM, away from the cell surface 
(Silbiger, Jacobsen et al. 1994; Yu, Yu et al. 2000). To elucidate the roles of TIMPs and their 
domains during development, I used mRNA microinjection to disrupt endogenous TIMP 
levels and overexpressed TIMP-2 and -3, or their individual N- or C-terminal domains in X. 
laevis embryos. Ectopic expression of TIMP-2 and -3 as well as their N- and C-terminal 
domains led to distinct developmental disruptions, suggesting MMP-dependent and 
independent functions. Additionally, zymography and PCR analysis showed that the TIMP 
N- and C-terminal domains led to differential changes in MMP activity, and the expression 
of marker genes, indicating that each domain has unique downstream effects.  
 
2.2 Materials and Methods 
2.2.1. Sequence analysis of vertebrate and invertebrate TIMP-2 and -3 N- and C-terminal 
domains 
 Sequence alignments and amino acid sequence identity were performed using 
ClustalW2 analysis software at the European Bioinformatics Institute site at 
http://www.ebi.ac.uk/Tools/clustalw2/index.html. Phylogenetic comparisons were performed 
using Molecular Evolutionary Genetic Analysis (MEGA) 5.2.1. software to construct a 
neighbour-joining tree with a bootstrap of 1000. 
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2.2.2. Animals 
 Adult X. laevis were purchased from Xenopus I Inc (Dexter, MI). Embryos were 
fertilized and reared in accordance with standard protocols (Sive H.L. 2000) and staged 
according to Nieuwkoop and Faber (Nieuwkoop P.D. 1956). Animals were housed and 
treated according to UWO and CCAC guidelines. 
 
2.2.3. Cloning of X. laevis TIMP-2 and -3 
 X. laevis TIMP-2 and TIMP-3 sequences were previously identified (AF042493 and 
MGC84288, respectively).  I cloned X. laevis TIMP-2 and -3 from total adult liver cDNA 
using SuperScriptTM Reverse Transcriptase (Invitrogen) with Platinum® Taq DNA 
Polymerase High Fidelity (Invitrogen). The coding regions of both TIMP-2 and -3 were 
cloned using specific primers based on the above sequences. The full-length TIMP-2 and -3 
amplicons were cloned into the pCR®II-TOPO vector (Invitrogen), and sequences were 
confirmed at the Robarts Research Institute DNA Sequencing Facility at the University of 
Western Ontario. 
 
2.2.4. Generation of TIMP-2 and -3 mRNA constructs for microinjection 
 PCR was used to generate full-length, N-terminal or C-terminal TIMP-2 and -3 
(hemagglutinin) HA-tagged constructs using the full-length clones as templates. Briefly, all 
TIMP constructs (T2FL, T2N, T2C, T3FL, T3N, T3C) were HA-tagged on their C-terminal 
ends. In addition, the two C-terminal domain constructs (T2C and T3C) were engineered to 
include their appropriate secretory signal sequence through a two-step PCR process. 
Following PCR amplification, the sequences of all amplicons were verified. All TIMP-2 and 
-3 constructs were subsequently ligated into the BglII/SpeI restriction sites of the T7TS 
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plasmid. mMessage mMachine (Ambion) was used with T7 RNA polymerase (Ambion) to 
synthesize  stable capped, poly(A)-tailed mRNA transcripts that were dissolved in filtered 
water. mRNA was quantified using Nanovue spectrophotometer (GE), and its integrity was 
assessed using 1% agarose gel electrophoresis. Green fluorescent protein (GFP) mRNA was 
generated and quantified in a similar way from a proven T7TS construct plasmid (Walsh, 
Cooper et al. 2007).   
 
2.2.5. mRNA microinjection 
 Prior to injection, fertilized X. laevis embryos at the 1 cell stage were transferred from 
0.1X Marc’s modified ringers (MMR) into 1X MMR containing 4% Ficoll. Embryos were 
injected at the 1 cell stage with TIMP-2 or -3 full-length, N-terminal, or C-terminal 
constructs using 10 µm diameter glass needles. Embryos were injected with 4 ng of mRNA 
construct in a volume of 2.3 nl. Embryos were maintained in 1X MMR with Ficoll for 5 hr 
following injection, then transferred to 0.1X MMR solution for rearing. Embryos that were 
dead or abnormal 2 hr post-injection were removed, and the remaining embryos (representing 
the 100% being monitored) were examined for phenotypic abnormalities. The percent of 
normal embryos present (no clear visible defects) were quantified for two days following 
injection. Mean values were obtained from 3 independent sets of experiments. 
 
2.2.6. Protein preparations and Western blotting 
 Stage 30 embryos injected with the various mRNA constructs, or uninjected controls, 
were subject to protein extraction. Briefly, 10 embryos were lysed and sonicated in 100 µl 
lysis buffer (150 mM NaCl, 50 mM Tris-HCl (pH 7.5), 1% Triton X-100, 0.1% SDS, 1% 
deoxycholate, 50 mM sodium flouride, 1 mM sodium orthovanadate, 0.1% NP-40 protease 
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inhibitor cocktail (Roche Applied Science, Indianapolis, IN)). Lysates were centrifuged at 
15,000 g for 15 min at 4°C, the supernatant was removed, and protein was quantified using 
BCA protein assay kit (Thermo Scientific) in accordance with the manufacturer’s 
instructions. Equal amounts of protein (25 µg) were electrophoresed on a 10% SDS gel and 
transferred to PVDF membrane (Bio-Rad). Membranes were washed three times with TBST 
(Tris-buffered saline containing 0.5% Tween 20), blocked using 5% skim milk in TBST for 
30 min at room temperature, and incubated overnight at 4°C with primary antibody. Primary 
antibodies used were rabbit anti-HA, 1/1000 dilution (Invitrogen) or mouse anti-β-actin, 
1/1000 dilution (Invitrogen). After washing 3 times in TBST, membranes were incubated 
with secondary antibody (goat anti-rabbit HRP, 1/5000 dilution; Invitrogen, or goat anti-
mouse HRP, 1/5000 dilution; Invitrogen) for 1 hr at room temperature. Membranes were 
washed 3 times in TBST and peroxidase activity was detected using SuperSignal West Pico 
Chemiluminescent Substrate (Thermo Scientific), and visualized, standardized to actin levels, 
and photographed using Bio-Rad Quantity One 4.4.0 software. 
 
2.2.7. Zymography 
Briefly, 12.5 µg of protein from injected embryos (as described above) was diluted 
1:1 with 2X SDS-loading buffer (0.5 M Tris-HCl (pH 6.8), 10% SDS, 2.5 % glycerol, 1% 
bromophenol Blue), and then analyzed by gelatin zymography. Protein samples were loaded 
into a 10% gelatin zymogram gel (Bio-Rad), and electrophoresed in 1X zymogram running 
buffer (25 mM Tris, 192 mM glycine, 0.1% SDS), followed by in-gel renaturation for 30 min 
at room temperature in renaturing solution (2.5% Triton X-100). Substrate cleavage was 
carried out by incubating gels in zymogram developing buffer (pH 7.5, 50 mM Tris, 200 mM 
NaCl, 5 mM CaCl2 (anhydrous), 0.02% Brij-35) for 48 hr at 37°C. The gelatinolytic activity 
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was visualized as a clear band in the blue background after staining with 0.5% Coomassie 
blue. Gels were visualized and photographed, and densitometry was performed using Bio-
Rad Quantity One 4.4.0 software. 
 
2.2.8. Real-Time PCR of marker genes 
 To investigate changes in the expression of embryonic genes following injection of 
the various TIMP constructs, real-time qPCR was performed using the CFX96™ Real-Time 
PCR Detection System (Bio-Rad) in a two-step procedure using PerfeCTa® SYBR® Green 
SuperMix (Quanta Biosciences). Amplification of the Ef-1α gene was performed to 
standardize the amount of sample cDNA. Primers, based on the X. laevis sequences, were as 
follows: Ef-1α 5’CTACAAATGTGGTGGCATCG and 5’GCTCTGCCTTCAGTTTGTCC; 
RECK 5’AGTGAAGGATGCACCAAACC and 5’GCAGTTCAGCACCATCAAGA; β1 
integrin 5’CTGACGCAGGATTCCATTTT and 5’GTGTACATGTTCCCGTGCAG; MMP-
2 5’AGGAGAAGGCCAAGTTGTGA and 5’CTGAGCGACCAGAATCAGTG; MMP-9 
5’CTGGGACTGAAGGAGACTGG and 5’CCCCCTCAAATGTGTTGAAT. All reactions 
were performed in a 96 well plate using the following cycling conditions: 40 cycles of 95 °C 
for 15 sec, 60 °C for 30 sec, and 72°C for 1 min. Using the ΔΔCT (delta-delta CT) method, 
the value of each control sample was set at 1 and used to calculate the fold change of target 
genes. 
 
2.3 Results and Discussion 
Understanding of TIMP function has been confounded by the realization that TIMPs 
may also bind to a variety of cell surface receptors through their C-terminal domains and 
mediate a number of cell signaling pathways in an MMP-independent manner (Lambert, 
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Dasse et al. 2004). There is currently little information regarding how TIMP proteins 
function in vivo, particularly as their domains may act through both MMP-dependent and 
independent mechanisms (Stetler-Stevenson 2008). In this study I examined the individual 
domains of TIMP-2 and -3 in early stage X. laevis embryos in order to gain an understanding 
of how the individual N- and C-terminal domains may regulate key developmental events, as 
there is evidence that TIMP N- and C-terminal domains may have unique properties, function 
independently as individual domains, and maintain their native topology (Bahudhanapati, 
Zhang et al. ; Chirco, Liu et al. 2006; Brew and Nagase 2010; Bahudhanapati, Zhang et al. 
2011; Wu, Wei et al. 2011). 
 
2.3.1. The N- and C-terminal domains of X. laevis TIMP-2 differ in their sequence 
conservation 
A direct comparison of amino acid sequence identities of the individual X. laevis 
TIMP-2 N- and C-terminal domains with other vertebrate and invertebrate species is of 
particular interest, as I investigated in vivo whether TIMP N- and C-terminal domains could 
function independently of one another, and how these roles may be reflected in their 
evolutionary conservation. My analysis indicated that for TIMP-2, the N-terminal MMP-
inhibitory domains were more highly conserved across most vertebrate species analyzed, 
including both mammals and non-mammals, than the C-terminal domains (Fig. 2.1 A), a 
finding that has been previously reported (Brew and Nagase 2010). This may reflect the fact 
that the N-terminal domain has only one primary role, to bind to and inhibit MMP activity. 
As the catalytic domains of MMPs are conserved across species (Van Wart and Birkedal-
Hansen 1990), this TIMP domain is also conserved. Interestingly, Caenorhabditis elegans 
TIMP-2 does not contain the region corresponding to the vertebrate C-terminal domain, 
! 51 
suggesting the possibility that the TIMP-2 C-terminal domain signaling mechanism evolved 
only in higher vertebrates. In contrast, the TIMP-2 C-terminal domains were slightly more 
variable (Fig. 2.1 A), suggesting that their role, presumably in cell signaling, may vary 
between species. The C-terminal domain may have evolved concomitant with changes in 
receptor and cell signaling pathways. However, phylogenetic analysis comparing the X. 
laevis TIMP-2 N- or C-terminal domains with other species showed that both the N- and C-
terminal domains had a similar branching patterns in their phylogenetic trees, but diverged at 
different rates (Fig. 2.1 B vs. C).  
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Figure 2.1. Evolutionary conservation of TIMP-2 N- and C-terminal domains. (A) 
Sequence analysis comparing amino acid sequence identity of X. laevis TIMP-2 N- and C-
terminal domains among several vertebrates and invertebrates. Light grey boxes represent 
species whose N-terminal domains were more highly conserved with X. laevis TIMP-2 than 
their C-terminal domains. Dark grey boxes represent species whose C-terminal domains were 
more highly conserved with X. laevis TIMP-2 than their N-terminal domains. (B) 
Phylogenetic tree showing sequence divergence among TIMP-2 N-terminal domains as 
generated by MEGA 5.2.1. software. (C) Phylogenetic tree showing sequence divergence 
among TIMP-2 C-terminal domains as generated by MEGA 5.2.1. software. The C. elegans 
sequence was removed from phylogenetic analysis as the C-terminal domain was missing. 
Accession numbers are as follows: Xenopus (Xenopus laevis) AF042493, Human  (Homo 
sapiens) AAB19474.1, Mouse (Mus musculus) AAA40446.1, Chicken (Gallus gallus) 
NP_989629.1, Zebrafish (Danio rerio) NP_878294.1, Fugu (Takifugu rubripes) 
BAE06264.1, Elegans (Caenorhabditis elegans) AAA96174. 
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2.3.2. The C-terminal domain of X. laevis TIMP-3 is conserved 
In contrast to TIMP-2, when I examined the individual domains of TIMP-3 I found 
the opposite trend; the TIMP-3 C-terminal domains were more conserved with X. laevis 
TIMP-3 than their N-terminal domains across all vertebrate species examined (Fig. 2.2 A).  
However, this relationship was not true for invertebrates, as the N-terminal domain of sea 
urchin TIMP-3 was more conserved. TIMP-3 is unique in that it is the only TIMP that binds 
directly to the ECM, and studies have shown that the C-terminal domain of TIMP-3 is 
important for facilitating this binding (Yu, Yu et al. 2000). Langton et al. (1998) expressed 
both full-length and truncated forms of TIMP-3 in Cos-7 cells, and demonstrated that full-
length and C-terminal TIMP-3 were able to bind to the ECM, whereas N-terminal TIMP-3 
could not (Langton, Barker et al. 1998). Therefore, the C-terminal domain of TIMP-3 may 
have a conserved role in mediating its attachment to the ECM, at least among vertebrate 
species, while its N-terminal domain functions to inhibit MMP activity. Phylogenetic 
analysis comparing X. laevis TIMP-3 N- and C-terminal domains with other species showed 
that, unlike TIMP-2, the two domains followed a slightly different evolutionary trend, 
suggesting that the individual domains in TIMP-3 evolved under different selective pressures 
(Fig. 2.2 B and C).  
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Figure 2.2. Evolutionary conservation of TIMP-3 N- and C-terminal domains. (A) 
Sequence analysis comparing amino acid sequence identity of X. laevis TIMP-3 N- and C-
terminal domains among several vertebrates and invertebrates. Light grey boxes represent 
species whose N-terminal domains were more highly conserved with X. laevis TIMP-3 than 
their C-terminal domains. Dark grey boxes represent species whose C-terminal domains were 
more highly conserved with X. laevis TIMP-3 than their N-terminal domains. (B) 
Phylogenetic tree showing sequence divergence among TIMP-3 N-terminal domains as 
generated by MEGA 5.2.1 software. (C) Phylogenetic tree showing sequence divergence 
among TIMP-3 C-terminal domains as generated by MEGA 5.2.1 software. Accession 
numbers are as follows: Xenopus (Xenopus laevis) MGC84288, Human (Homo sapiens) 
AAB60373.1, Mouse (Mus musculus) AAA40447.1, Cow (Bos taurus) NP_776898.2, Fugu 
(Takifugu rubripes) BAE06261.1, Salmon (salmo salar) ACN10551.1, Sea Urchin 
(Strongylocentrotus purpuratus) XP_781027.1. 
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2.3.3. Overexpression of full-length TIMP-2 and -3 resulted in different developmental 
phenotypes 
To assess the roles of TIMP-2 and -3 during X. laevis development, I generated and 
overexpressed full-length TIMP-2 or -3 mRNA constructs in newly fertilized X. laevis 
embryos. Embryos were injected at the 1 cell stage and analyzed for gross morphological 
changes in development until stage 30 (approximately 2 days following injection). Real-time 
PCR analysis was used to confirm upregulation of TIMP-2 or -3 mRNA levels following 
injection of each construct. This verified that injected embryos all contained relatively equal, 
but elevated levels of TIMP mRNA compared with uninjected embryos. Additionally, to 
compare relative protein levels following injection, Western blotting against HA-tags was 
used. This confirmed that all proteins produced were present in equal amounts (Fig. 2.3). The 
percentage of normal embryos (embryos that were alive and morphologically normal) was 
determined and quantified at stage 15 (one day post-injection) and stage 30 (two days post-
injection). Over 90% of control uninjected embryos and embryos injected with GFP mRNA 
developed normally during this 48 hr period (Fig. 2.4 A and B). In comparison, injection of 
embryos with full-length TIMP-2 or -3 (T2FL and T3FL, respectively) mRNA resulted in 
serious developmental defects, with T3FL being more detrimental than T2FL (Fig. 2.4 A and 
B). By stage 30, 55% of T2FL injected embryos developed normally, whereas only 
approximately 10% of T3FL injected embryos developed normally (Fig. 2.4 A and B).  
Phenotypically, T2FL injected embryos displayed axial defects (truncated, curved axes), and 
neural tube closure failure (Fig. 2.5 A). In contrast, while overexpression of T3FL also 
resulted in axis defects (truncated, curved axes), these embryos did not display neural tube 
closure defects. 
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Figure 2.3. Microinjection of 4 ng of TIMP-2 or -3 mRNA constructs produces equal 
amounts of HA-tagged protein in X. laevis embryos. Following the injection of equal 
amounts of mRNA (4 ng) at the 1 cell stage, protein was isolated from stage 30 embryos. 
Equal amounts of protein were electrophoresed on a 10% SDS gel. TIMP constructs were 
detected using an anti-HA antibody. Images are of representative bands after normalization 
to β-actin levels. The left panel shows bands corresponding to TIMP-2 full-length (T2FL), N-
terminal (T2N), and C-terminal (T2C) constructs. TIMP-3 full-length (T3FL), N-terminal 
(T3N), and C-terminal (T3C) constructs are shown in the right panel. 
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2.3.4. Overexpression of TIMP-2 N- or C-terminal domain constructs resulted in more 
developmental defects than overexpression of full-length TIMP-2 
Overexpression of the individual N- or C-terminal domains of TIMP-2 resulted in 
distinctive survival rates as well as developmental defects. Following injection of either 
domain of TIMP-2 (T2N and T2C constructs), embryos displayed morphological defects 
similar to T2FL injected embryos (truncated, curved axes, and neural tube closure failure; 
Fig. 2.5 A); however, the effects were more severe as less than 30% of T2N and T2C injected 
embryos developed normally, compared to 55% normal development with the T2FL 
construct (Fig. 2.4 A). The two domains also manifested their effects at different rates, as by 
stage 15 only 30% of T2N injected embryos developed normally, versus 50% normal at this 
time point with the T2C construct. Thus, the T2N construct was more detrimental at this time 
point (Fig. 2.4 A). By stage 30, T2N and T2C injected embryos displayed similar scores with 
only 21% and 26% normal development, respectively, both of which were more detrimental 
than the T2FL injections (Fig. 2.4 A). Overexpression of T2FL, T2N, and T2C constructs all 
produced large-scale morphological defects including head defects, curved, truncated axes, 
and failure of the neural tube to close (Fig. 2.5 A; see appendix C for additional images). 
Since overexpression of all three constructs disrupted the proper formation of the neural tube, 
this suggests that a combination of both TIMP-2 cell signaling (via the C-terminal end) and 
MMP-inhibitory activity (via the N-terminal end) may be required for normal development 
of the neural tube.  
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2.3.5. Overexpression of full-length TIMP-3 or its N-terminal domain construct resulted in 
more developmental defects than overexpression of the TIMP-3 C-terminal domain 
construct 
The consequences of injecting full-length TIMP-3 and its N- or C-terminal domain 
did not follow the same pattern as TIMP-2. T3FL injections caused a variety of defects that 
resulted in only 15% normal embryos by stage 30 (Fig. 2.4 B). A similar rate of defects was 
also displayed in T3N injected embryos (Fig. 2.4 B), and both T3FL and T3N injected 
embryos also had truncated, curved axes and head and eye malformation (Fig. 2.5 B). These 
defects and phenotypes were in contrast to the T3C injected embryos, which had over 70% 
normal development at stage 30 (Fig. 2.4 B). Indeed, most surviving T3C embryos displayed 
little to no morphological defects (Fig. 2.5 B; see Appendix C for additional images). Thus, I 
observed that T3FL and T3N constructs were approximately 5-fold more toxic to X. laevis 
embryos than T3C (15% vs 70% normal at stage 30; Fig. 2.4 B). In contrast, the T2N and 
T2C constructs were more than twice as toxic as T2FL (Fig. 2.4 A). The observation that 
T3FL and T3N overexpression resulted in developmental defects including curved, truncated 
axes, as well as anterior malformations, was consistent with in situ hybridization studies that 
showed TIMP-3 expression in the head and eye (Pickard and Damjanovski 2004). 
Additionally, T3FL and T3N constructs resulted in high levels of lethality compared with 
T3C (Fig. 2.4 B), and T3C overexpression resulted in embryos that did not display any 
serious development defects (Fig. 2.5 B). This indicates that it is the N-terminal domain of 
TIMP-3 that is involved in mediating developmental events, and this likely occurs through 
direct inhibition of MMP activity. The C-terminal domain of TIMP-3 on its own appears to 
play no major role in development at this time. 
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Figure 2.4. Overexpression of TIMP-2 and -3 led to abnormal development. Following 
the injection of mRNA constructs at the 1 cell stage, embryos were scored for a normal 
phenotype at stage 15 and stage 30 in development. The percent of normal embryos 
following the injection of each construct was monitored and graphed. (A) Injections 
consisted of 4 ng of mRNA encoding either TIMP-2 full-length (T2FL, red circle), N-
terminal domain (T2N, purple triangle), or C-terminal domain (T2C, blue square) constructs, 
or GFP (green circle). X represents uninjected controls. (B) Injections consisted of 4 ng of 
mRNA encoding TIMP-3 full-length (T3FL, red circle), N-terminal domain (T3N, purple 
triangle), or C-terminal domain (T3C, blue square) constructs, or GFP (green circle). X 
represents uninjected controls.  Results are based on the average of 3 independent sets of 
experiments, where a minimum of 100 embryos were injected and counted for each replicate. 
Bars indicate standard error (SE).  
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Fig. 2.5 Overexpression of TIMP-2 and -3 resulted in specific morphological defects. 
Four nanograms of mRNA encoding either GFP, or full-length, N-terminal or C-terminal 
domain TIMP-2 or -3 were injected into X. laevis embryos at the 1 cell stage. Following 
injection, photographs were taken of representative embryos at stage 30. Anterior is to the 
left. GFP injected embryos were phenotypically normal. (A) Overexpression of TIMP-2 full-
length (T2FL), N-terminal (T2N) or C-terminal (T2C) constructs all caused similar early 
developmental defects, and neural tube closure failure. (B) TIMP-3 full-length (T3FL) and 
N-terminal (T3N) constructs resulted in axial defects and curvature. The C-terminal domain 
TIMP-3 (T3C) construct did not produce severe malformations. Images are of representative 
embryos where results were consistent between 3 independent sets of experiments, with a 
minimum of 100 embryos injected per construct for each experiment. See appendix C for 
additional images. 
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2.3.6. Overexpression of TIMP constructs resulted in differential changes in MMP-2 and   
-9 activity 
Gelatin zymography was used to determine whether overexpression of TIMP-2 or -3, 
or their individual domains altered the levels of active MMPs in developing embryos. I 
looked specifically at the activities of MMP-2 and -9, as these are two potent ECM 
remodelling proteins that have been shown to play important roles during development 
(Carinato, Walter et al. 2000; Zhang, Bai et al. 2003). Interestingly, overexpression of all 
TIMP constructs resulted in increased levels of active MMP-9, which was relatively low in 
control embryos, whereas TIMP-mediated changes in active MMP-2 (which was 
comparatively higher in control embryos) were much more subtle (Fig. 2.6). While it is 
counterintuitive that none of the TIMP constructs resulted in decreased MMP-9 activity 
relative to control embryos, (particularly the N-terminal constructs), the process of gelatin 
zymography separates TIMP-MMP complexes, and as such, is a measure of the amount of 
active MMP present in the embryo, as opposed to a direct measure of in vivo TIMP inhibition 
of MMP activity (Toth and Fridman 2001). The observed increases in MMP-9 seen here 
could have resulted from compensation in the embryos, whereby increasing the amount of 
active MMP was a response to the attenuation of nascent MMP activity due to the injected 
TIMP construct. Accordingly, the highest levels of active MMP-9 were observed in embryos 
injected with T2N and T3FL constructs (Fig. 2.6), both of which would function mainly in 
MMP inhibition. Additionally, this supports my embryo viability data, as these constructs 
resulted in the most severe developmental phenotypes, with only 21% and 15% normal 
development, respectively. With TIMP-3, the T3N construct also resulted in increased levels 
of active MMP-9, however, not to the same extent as observed in the T3FL injected embryos 
(Fig. 2.6). This was unexpected as both constructs should be involved predominantly in 
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MMP inhibition, and the embryo viability data for both constructs was remarkably similar, 
resulting in only approximately 15% survival by stage 30. This further highlights the distinct 
functions seen between the N-terminal domains of TIMP-2 and -3, as reflected by their 
distinct sequence conservation patterns between species.  
The T3C construct caused very minor changes in MMP activity relative to control 
embryos (Fig. 2.6), which corroborated my embryo viability data as injection with this 
construct also resulted in very minor phenotypic abnormalities and 70% normal development 
(Fig. 2.5 B). This provided further support that the TIMP-3 C-terminal domain plays no 
independent role in early X. laevis development. Interestingly, the T2C construct did result in 
increased levels of MMP-9 relative to control embryos. This increase, however, was not as 
dramatic as that observed in T2N or even T2FL injected embryos (Fig. 2.6), even though 
injection with the T2C construct was comparable with the T2N construct in terms of lethality 
in the embryos (Fig. 2.5 A). This supports the idea that the C-terminal domain of TIMP-2 
may work through a different mechanism to regulate MMPs during development.  
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Figure 2.6. Overexpression of TIMP-2 or -3 and their individual domains altered MMP-
2 and -9 activity in X. laevis embryos. Gelatin zymography was used to measure changes in 
MMP-2 and MMP-9 activity resulting from overexpression of 4 ng of TIMP-2 full-length 
(T2FL), N-terminal (T2N), C-terminal (T2C), or TIMP-3 full-length (T3FL), N-terminal 
(T3N), or C-terminal (T3C) mRNA constructs. Proteins were extracted from embryos at 
developmental stage 30, following injection of each TIMP construct. Active MMP-9 (84 
KDa) and MMP-2 (63 KDa) are visualized as bright bands against a dark background.  
Densitometry readings were used to quantify and graph changes in MMP-9 (dark grey) and 
MMP-2 (light grey) activities relative to control (uninjected) embryos. Graphed data is from 
one representative experiment, where trends and relative levels were observed consistently in 
at least 3 trials. 
MMP-9 
(84 KDa) 
MMP-2 
(63 KDa) 
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2.3.7. Real-time PCR analysis of marker genes in post-TIMP construct injected embryos 
To better understand the phenotypes I observed following overexpression of TIMP-2 
or -3 or their individual domains, I performed quantitative real-time PCR on injected 
embryos to look for changes in key genes associated with TIMP-2 and -3 activity. 
Specifically, I assayed for changes in MMP-2 and -9 expression as well as for changes in 
RECK and β1 integrin expression (Fig. 2.7 A and B). My results showed that none of the 
TIMP constructs altered RECK or β1 integrin expression levels substantially. It is noteworthy 
that neither T2C nor T2FL constructs resulted in substantial decreases in RECK expression 
levels (though the trend was towards a decrease), as this relationship has previously been 
demonstrated in mouse and human cell lines (Oh, Seo et al. 2004).  However, previous 
studies were carried out with homogenous cell populations in vitro, whereas embryos contain 
many types of cells, only some of which may be able to bind to TIMPs and modulate RECK 
expression. A more careful analysis must be carried out to examine the possibility of 
localized changes in RECK or β1 integrin levels in response to TIMP signaling.   
 Although RECK expression remained largely unaltered, my results indicated that T2C 
may have a role in mediating other important signaling events during X. laevis development. 
Real-time PCR showed that the T2C construct resulted in dramatic decreases in MMP-2 and -
9 expression (decreased 14 and 15 fold, respectively) compared with controls (Fig. 2.7 A).  
As my zymography data indicated that MMP activity is upregulated at the time, this decrease 
in transcript is puzzling. However, while increased MMP activity in vivo could be achieved 
through the activation of existing pro-MMPs, the change in transcript levels may reflect a 
cell signaling function of the T2C construct that is independent of the function of a native 
whole TIMP molecule. As such, the embryo is responding to signals mediated by a protein 
domain that is no longer linked to the usual activities of the entire molecule.  Consequently, 
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genes are regulated in a fashion that is not normal and thus, detrimental.  The T2N construct 
also decreased MMP-9 expression, however, only by about 4-fold, and T2FL showed 
comparable results. The less marked changes in expression following injection with T2FL 
and T2N constructs may be the result of an MMP-dependent regulatory feedback 
mechanism, as injection of T3FL and T3N constructs resulted in comparable changes in 
MMP-2 and -9 expression (Fig. 2.7 B). Since the T2C construct does not have any MMP-
inhibitory activity, the observed decreases in MMP-2 and -9 expression are likely due to an 
MMP-independent TIMP-2 mediated signaling cascade. Indeed, recent research has shown 
that the TIMP-2 C-terminal domain may be involved in a variety of cell signaling cascades, 
including receptor tyrosine kinase (RTK), NF-κB, and cell proliferation pathways (Murphy, 
Unsworth et al. 1993; Seo, Li et al. 2003; Sun and Stetler-Stevenson 2009). In addition, I 
have unpublished data which showed that the T2C construct can bind to the surface of X. 
laevis A6 cells, indicating that there is at least one potential cell surface binding partner for 
the C-terminal domain of TIMP-2 to signal through in X. laevis. Interestingly, the unique 
TIMP-2 C-terminal signaling cascade could be species specific as sequence analysis suggests 
that this domain is less conserved than its N-terminal counterpart (Fig. 2.1; see appendix D 
for table of PCR CT values). 
 In contrast, the T3C construct did not result in considerable changes in gene 
expression (Fig. 2.7 B). This is consistent with the fact that I did not observe any large-scale 
morphological changes in T3C injected embryos, and supports the conclusion that the C-
terminal domain of TIMP-3 is likely only involved in mediating binding of TIMP-3 to 
components of the ECM.  
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Figure 2.7.  Effect of full-length TIMP-2 or -3 and their N- and C-terminal domains on 
transcript levels. Real-time PCR was used to measure the changes in transcript levels 
following the injection of 4 ng of (A) TIMP-2 full-length (T2FL), N-terminal (T2N), or C-
terminal (T2C), or (B) TIMP-3 full-length (T3FL), N-terminal (T3N), or C-terminal (T3C) 
mRNA constructs into X. laevis embryos at the one cell stage. Changes in transcript levels 
were measured relative to Ef-1α and normalized to control (uninjected) embryos. INTG Beta 
1 represents β1 integrin. Results are based on the average of 3 independent sets of 
experiments. Bars indicate SE (see appendix D for table of  PCR CT values).  
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2.4 Conclusions 
Taken together, I observed that while the N- and C-terminal domains of TIMP-2 were 
similar in their patterns of evolutionary conservation, the two domains differed in their 
abilities to alter gene expression and MMP activity. The misregulation of either domain had 
severe consequences on development, more so than the overexpression of full-length TIMP-
2. This suggested that both domains of TIMP-2 serve a unique function, one MMP-
dependent, one MMP-independent, where their function is mediated and moderated when 
they are part of the whole TIMP-2 molecule. In contrast, the TIMP-3 domains differed in 
their patterns of divergence, and the C-terminal domain had little effect on gene expression 
or MMP activity. With TIMP-3, however, misregulation of the full-length molecule was 
most detrimental, suggesting that the molecule works as a whole, and that there is little or no 
MMP-independent function, at least at the developmental stages examined in this study. 
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CHAPTER THREE 
 
FUNCTIONAL CHARACTERIZATION OF TISSUE INHIBITOR OF 
METALLOPROTEINASE -1 (TIMP-1) N- AND C-TERMINAL DOMAINS DURING 
XENOPUS LAEVIS DEVELOPMENT !!!!!!!!!!!!!!!!
 
 
 
This work has been submitted as “Nieuwesteeg, M. A., Willson, J.A.,  Cepeda, M., Fox, 
M.A. and Damjanovski, S. (2013). Functional characterization of tissue inhibitor of 
metalloproteinase-1 (TIMP-1) N- and C-terminal domains during Xenopus laevis 
development. PlosOne manuscript ID: PONE-D-13-19519.” The text has been modified from 
the original manuscript to adhere to formatting guidelines for this thesis. Experiments were 
designed and carried out by M.A.N., J.A.W. assisted with embryo rearing, M.C. assisted with 
reverse zymography, M.A.F. assisted with Western blotting, S.D. provided funding, 
resources, and intellectual contributions.  
! 77 
3.1 Introduction 
3.1.1. ECM dynamics in development 
MMPs are important regulators of development due to their ability to cleave 
structural components of the ECM, as well as secreted signaling molecules within the ECM, 
leading to changes in both cell movement and cell signaling (Vu and Werb 2000). Controlled 
inhibition of MMP activity is needed to prevent excessive ECM degradation, and is largely 
carried out by TIMPs, as well as the cell surface MMP inhibitor, RECK (Nagase, Visse et al. 
2006). Maintaining the proper balance between MMP activity and inhibition is necessary 
during embryogenesis and facilitates developmental events including organogenesis and 
angiogenesis (Liotta, Steeg et al. 1991; Blelloch and Kimble 1999), and disrupting this 
balance can have deleterious effects (Zhang, Bai et al. 2003; Pickard and Damjanovski 
2004). Inhibition of MMP-2 or -9, two potent ECM proteases, can lead to axial defects and 
incomplete neural crest cell migration, respectively, while knockout of membrane-bound 
MMP-14 (MT1-MMP) during mouse development is embryonic lethal (Zhou, Apte et al. 
2000; Hasebe, Hartman et al. 2007; Monsonego-Ornan, Kosonovsky et al. 2012). Knockout 
of RECK during development is also lethal due to defects in angiogenesis (Oh, Takahashi et 
al. 2001). Additionally, my research has shown that overexpression of TIMP-2 and -3 during 
Xenopus laevis development leads to axial and neural tube defects (Chapter 2) (Nieuwesteeg, 
Walsh et al. 2012).  Thus, disruption of activity levels in this proteolytic ECM remodeling 
network is detrimental during development. 
 
3.1.2. Structure and function of TIMPs 
Although TIMPs are a family of only 4 secreted proteins (TIMP 1-4), together they 
can inhibit all known MMPs by binding to MMPs in a 1:1 manner to block their proteolytic 
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activity (Murphy 2011). As discussed in section 1.3.1., the four mammalian TIMPs share 
similar domain structure and roughly 40% amino acid sequence similarity, including 12 
conserved cysteine residues which result in the formation of 6 disulfide bonds (Nagase, 
Meng et al. 1999).  The structurally and functionally distinct N- and C-terminal domains of 
TIMP proteins are each stabilized by 3 disulfide bonds (Nagase, Meng et al. 1999). The N- 
and C-terminal domain boundary is found between cysteines 6 and 7, in between which there 
are only one or two amino acids (see Fig. 1.1, section 1.3.1). The N-terminal domain of a 
TIMP is both necessary and sufficient for MMP inhibition, and sequesters MMP activity by 
binding to the zinc active site found in the catalytic domain of all MMPs (Gomez, Alonso et 
al. 1997). In contrast, the smaller C-terminal domain of TIMPs may influence cell behavior 
in an MMP-independent manner through direct regulation of a number of cell signaling 
pathways (Chirco, Liu et al. 2006). As previously discussed, characterization of cell surface 
binding partners and specific signaling events involving TIMP C-terminal domains has been 
carried out in vitro, where activation of a resultant signaling pathway varies with the specific 
TIMP expressed, as well as the cell type each TIMP is expressed in (Bourboulia and Stetler-
Stevenson 2010).   
 
3.1.3. TIMP-1 overview 
TIMP-1 was first identified for its erythroid potentiating activity, and as an inhibitor 
of metalloproteinases (Docherty, Lyons et al. 1985; Gasson, Golde et al. 1985). Both the N- 
and C-terminal domains of TIMP-1 have now been well characterized in vitro. The two 
domains of TIMP-1, as well as of the other TIMPs, have the ability to fold and function 
autonomously in vitro (Gomez, Alonso et al. 1997; Bahudhanapati, Zhang et al. 2011; 
Nieuwesteeg, Walsh et al. 2012). TIMP-1 can inhibit MMP-2 and -9, which are two powerful 
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ECM proteases that cleave abundant ECM components (Nagase, Visse et al. 2006; Shah, 
Shukla et al. 2009). Through its C-terminal domain, TIMP-1 has been linked to regulation of 
specific cell signaling pathways. TIMP-1 has been shown to promote cell proliferation 
(Hayakawa, Yamashita et al. 1992), although the receptor-mediated events involved in this 
pathway remain unidentified. More recently, TIMP-1 has been associated with inhibition of 
apoptosis in several human cell lines (Guedez, Stetler-Stevenson et al. 1998; Li, Fridman et 
al. 1999). TIMP-1 may also increase the abundance of cellular survival and differentiation 
factors, and this activity has been linked to association of TIMP-1 with cell-surface CD63 
and β1 integrin (discussed in section 1.6.2.) (Guedez, Stetler-Stevenson et al. 1998; 
Berditchevski and Odintsova 1999; Guedez, Mansoor et al. 2001; Jung, Liu et al. 2006). To 
date, however, the unique activities of the individual TIMP-1 domains have not been well 
characterized in vivo, and the specific roles of the two domains as they pertain to 
development remain unknown. 
 
3.1.4. Summary and experimental approach 
I have previously preformed a series of domain specific overexpression experiments, 
which suggested that the TIMP-2 and -3 N- and C-terminal domains may have specific 
MMP-dependent and independent functions, respectively, during embryogenesis in X. laevis 
(Chapter 2) (Nieuwesteeg, Walsh et al. 2012). In the present study, I used a similar approach 
to characterize the unique functions of the TIMP-1 N- and C-terminal domains during early 
X. laevis development. Here I show that the TIMP-1 C-terminal domain can act 
autonomously to alter gene expression and MMP levels in X. laevis embryos, and that axial 
and head defects resulting from C-terminal domain overexpression are different than those 
observed with the N-terminal domain.   
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3.2 Materials and Methods 
3.2.1. Cloning of X. laevis TIMP-1 
 X. laevis TIMP-1 was cloned using primers designed from unannotated X. laevis 
clone  AAI41767.1. Primers used were Forward: 5’-GACAGAAGGACTGCCCAGCC-3’ 
and Reverse: 5’-CAAAACACTTCTCCTTCGAG-3’.  Xenopus laevis TIMP-1 was isolated 
from total cDNA from stage 35 embryos using SuperScriptTM Reverse Transcriptase (Life 
Technologies) with Platinum® Taq DNA Polymerase High Fidelity (Life Technologies). The 
full-length TIMP-1 amplicon was cloned into the pCR®II-TOPO vector (Life Technologies), 
and the sequence of full-length X. laevis TIMP-1 was confirmed at the Robarts Research 
Institute DNA Sequencing Facility at the University of Western Ontario, and submitted to 
Genbank as: KF018236 (see Appendix A for coding sequence). 
 
3.2.2. Comparison of amino acid identity between vertebrate TIMP-1 N- and C-terminal 
domains 
 Sequence alignments and amino acid sequence identity were performed using 
ClustalW2 analysis software from the European Bioinformatics Institute website 
(http://www.ebi.ac.uk/Tools/clustalw2/index.html), using default settings. Phylogenetic 
comparisons were performed using MEGA 5.2.1. software to construct a neighbour-joining 
tree with a bootstrap of 1000. Accession numbers of known full-length TIMP-1 proteins were 
as follows: Human (Homo sapiens) NP_003245.1; Mouse (Mus musculus) AAH51260.1; Rat 
(Rattus norvegicus) EDL97726.1; Cow (Bos taurus) AAP44413.1; Horse (Equus caballus) 
NP_001075984.1; Rabbit (Oryctolagus cuniculus) AAW79053.1; Shark (Callorhinchus 
milii) AFK11387.1;  Newt (Notophthalmus viridescens) ABB88702.1. 
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3.2.3. Animals 
Adult X. laevis were purchased from Ward’s Natural Science (Rochester, NY), and 
fertilized, reared and housed as described in section 2.2.2. 
 
3.2.4. Generation of TIMP-1 mRNA constructs for microinjection 
 PCR was used to generate full-length (T1FL), N-terminal (T1N) or C-terminal (T1C) 
TIMP-1 HA-tagged constructs using the full-length clone as a template. Briefly, all TIMP-1 
constructs (T1FL, T1N, T1C) were HA-tagged on their C-terminal end. The C-terminal 
domain construct (T1C) was engineered to include its appropriate secretory signal sequence 
through a two-step PCR process. Primers were as follows: T1FL forward 5’- 
AGATCTATGTTGTACCTTGTGGTTGTG -3’ and T1FL reverse 5’- 
CAGTCTGCTGCCACAACACAATACCCATACGATGTTCCAGATTACGCTACTAGT -
3’; TIN forward 5’- AGATCTATGTTGTACCTTGTGGTTGTG and T1N reverse 
GTGTATCGCAAAGCCTGTTCCTACCCATACGATGTTCCAGATTACGCTACTAGT-
3’; T1C signal sequence forward 5’-AGATCTATGTTGTACCTTGTGGTTGTG-3’ and T1C 
signal sequence reverse link 5’- 
CTCAGCCAGGAGGTGTTGGGGTGCAACATCGTCCCCTGCTAT-3’, and C-terminal 
domain forward link 5’-TGCAACATCGTCCCCTGCTAT-3’ and C-terminal domain 
reverse     5’-
CAGTCTGCTGCCACAACACAATACCCATACGATGTTCCAGATTACGCTACTAGT-
3’.  Following PCR amplification, the sequence of all amplicons was verified. All TIMP-1 
constructs were subsequently ligated into the EcoRV/SpeI restriction sites of the T7TS 
plasmid. An mMessage mMachine in vitro transcription kit was used with T7 RNA 
polymerase (Ambion) to synthesize stable capped, poly(A)-tailed mRNA transcripts that 
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were dissolved in filtered water. mRNA was quantified using Nanovue spectrophotometer 
(GE), and its integrity was assessed using 1% agarose gel electrophoresis. GFP mRNA was 
generated and quantified in a similar manner from a proven T7TS-GFP construct plasmid 
(Walsh, Cooper et al. 2007). 
 
3.2.5. mRNA microinjection 
 Embryos at the 1 cell stage were injected with 4 ng of TIMP-1 full-length, N-
terminal, or C-terminal (T1FL, T1N, T1C) mRNA constructs in a volume of 2.3 nl as 
described in section 2.2.5. Embryos that were dead or abnormal 2 hr post-injection were 
removed, and the remaining embryos (representing the 100% being monitored) were 
observed for phenotypic abnormalities. The percent of normal embryos (no visible defects) 
was quantified for two days following injection (until stage 30 in development). Mean values 
were obtained from 3 independent sets of experiments. 
 
3.2.6. Semi-quantitative RT-PCR analysis 
Semi-quantitative RT-PCR analysis was used to examine changes in proteolytic gene 
expression patterns, or to confirm upregulation of TIMP-1 following injection with T1FL, 
T1N, or T1C constructs compared to control embryos. Total RNA was extracted from 
injected and control embryos using RNeasy Mini Kit (Qiagen) and 1 µg RNA was reverse 
transcribed using qScriptTM cDNA Supermix (Quanta Bioscienes). PCR was carried out using 
KAPA Taq PCR Kit (KAPA Biosystems) and Eppendorf Thermal Cycler. The cycling 
conditions were as follows: initial denaturation, 95°C for 2 min, followed by 28 cycles of the 
following: denature 95°C 30 sec, anneal 55°C 30 sec, extend 72°C 30 sec.  Primers, based on 
the X. laevis sequences, were as follows: Ef-1α 5’-TGTTGGCAGAGTGGAGACTG-3’ and 
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5’-GGCCAAGTGGAGGATAGTCA-3’; TIMP-2 5’-AGGTAAAGCCGATGGTGATG-3 
and 5’-GCCTGTCGTCCGTTTATGTT-3’; TIMP-3 5’-TTCCAAGAACGAGTGCCTCT-3’ 
and 5’-GGGATCCGTGGTGTTTATTG-3; RECK 5’GGATGTTTACAGGTCTACCC-3’ 
and 5’ GGCTCTGTTCCTCCAAAGAT-3’; MT1-MMP 5’-
CTATGAGGCGATTCGGAGAG-3’ and 5’-GCCACCAGGAACAGATCATT-3’; MMP-2 
5’-TGATTCTGGTCGCTCAGATG-3’ and 5’-CTTGTTTCCCAGGAAGGTGA-3’; MMP-9 
5’-AGGACCATGGGGATCCTTAC-3’ and 5’-AACACAAGGCTGCCCATTAC-3’; T1FL 
and T1C 5’-ATGTTGTACCTTGTGGTTGT-3’ and 5’-TTATTGTGCTGTGCAGCAG-3’; 
T1N 5’- ATGTTGTACCTTGTGGTTGT-3’ and 5’-GGAACAGGCTTTGCGATACAC-3’.   
 
3.2.7. Protein preparations and Western blotting 
 Stage 30 embryos injected with T1FL, T1N or T1C mRNA constructs, or uninjected 
controls, were subject to protein extraction. Briefly, 10 embryos were lysed and sonicated in 
100 µl modified RIPA buffer (150 mM NaCl, 50 mM Tris (pH 8.0), 1.0% NP-40, 0.5% 
sodium deoxycholate, 0.1% SDS, 10µl/ml HaltTM Protease Inhibitor Cocktail (Thermo 
Scientific) and 10 µL/ml HaltTM Phosphatase Inhibitor Cocktail (Thero Scientific)) and 
lysates were centrifuged at 15,000 g for 25 min at 4°C. The supernatant was removed and 
protein was quantified using BCA protein assay kit (Thermo Scientific) according to 
manufacturer’s instructions. Electrophoresis and Western blotting was performed as 
previously described in section 2.2.6. Primary antibodies used were rabbit anti-HA antibody 
(1:1000 dilution; Santa Cruz) or mouse anti-β-actin antibody (1:1000 dilution; Santa Cruz). 
Secondary antibodies used were goat anti-rabbit HRP (1:5000 dilution; Life Technologies) or 
goat anti-mouse HRP (1:5000 dilution; Bio-Rad). Western blots were visualized and 
photographed using Bio-Rad Quantity One 4.4.0 software.  
! 84 
 
3.2.8. Zymography and reverse zymography 
12.5 µg of protein (as extracted in section 3.2.7.) from T1FL, T1N or T1C injected 
embryos, or uninjected control embryos was diluted 1:1 with 2X SDS-loading buffer (0.5 M 
Tris-HCl, pH 6.8, 10% SDS, 2.5 % glycerol, 1% Bromophenol Blue). For zymography, 
protein samples were electrophoresed on a 1% gelatin, 10% polyacrylamide gel. For reverse 
zymography, protein was electrophoresed on a 1% gelatin, 15% polyacrylamide gel co-
polymerized with MMP-conditioned media from Hs578t cells according to Hawkes et al. 
(2010). Hs578t cells were chosen for their ability to secrete high levels of MMPs, particularly 
MMP-2 and -9. For both zymography and reverse zymography, gels were electrophoresed in 
1X zymogram running buffer (25 mM Tris, 192 mM glycine, 0.1% SDS), followed by in-gel 
renaturation for 30 min at room temperature in renaturing solution (2.5%Triton X-100). 
Substrate cleavage was carried out by incubating gels in zymogram developing buffer (pH 
7.5, 50 mM Tris, 200 mM NaCl, 5 mM CaCl2 (anhydrous), 0.02% Brij-35) for 48 hr at 37°C. 
For zymography, MMP activity was visualized as clear bands against blue background after 
staining with 0.5% Coomassie blue (Bio-Rad). For reverse zymography, TIMP activity was 
visualized as dark bands against light background after staining with 0.5% Coomassie blue 
(Bio-Rad).  Gels were visualized and photographed, and densitometry was performed using 
Bio-Rad Quantity One 4.4.0 software. 
 
3.2.9. Statistical analysis 
 All statistical analysis was performed using the IBM SPSS Statistic 19 program. 
Results were presented as mean ± SE. Statistical significance was determined using one-way 
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ANOVA variance analysis and Dunnett’s multiple comparisons tests. Differences were 
considered statistically significant when p < 0.05.  
 
3.3 Results 
3.3.1. Amino acid sequence conservation of vertebrate TIMP-1 N- and C-terminal domains 
A direct amino acid sequence comparison of the individual TIMP-1 N- and C-
terminal domains between species has not previously been reported. Current full-length 
TIMP-1 protein sequences were identified, which thus far have only been confirmed in 
vertebrates. To investigate whether the unique functions of these domains may be concurrent 
with their patterns of evolutionary conservation, I cloned X. laevis TIMP-1 (GenBank: 
KF018236) and compared its N- and C-terminal domains with known mammalian and non-
mammalian TIMP-1 sequences. The N-terminal domain of X. laevis TIMP-1 was more 
highly conserved than its C-terminal domain with 7 of 9 vertebrate species analyzed (Fig. 3.1 
A). In general, the N-terminal domains of all species were more highly conserved than the C-
terminal domains, with the exception of horse and cow, where the C-terminal domains were 
more highly conserved between species (Fig. 3.1 A). Phylogenetic analysis of TIMP-1 N- 
and C-terminal domains with other vertebrate species showed the two domains follow a 
different evolutionary trend, as the branching patterns of the two trees differed, indicating 
that both domains evolved under different selective pressures (Fig. 3.1 B and C).  
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Figure 3.1. Evolutionary conservation of TIMP-1 N- and C-terminal domains differed. 
(A) Sequence analysis comparing amino acid sequence identity of X. laevis TIMP-1 N- and 
C-terminal domains versus known vertebrate species. Light purple boxes represent species 
whose N-terminal domains were more highly conserved with X. laevis TIMP-1 than their C-
terminal domains. Light pink boxes represent species whose C-terminal domains were more 
highly conserved with X. laevis TIMP-1 than their N-terminal domains. Blue boxes represent 
species with equal conservation with both X. laevis TIMP-1 N- and C-terminal domains. (B) 
Phylogram representation of sequence divergence among TIMP-1 N-terminal domains as 
generated by MEGA 5.2.1. software. (C) Phylogram representation of sequence divergence 
among TIMP-1 C-terminal domains as generated by MEGA 5.2.1. software.   
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3.3.2. TIMP-1 mRNA and protein was upregulated in X. laevis embryos following ectopic 
expression of TIMP-1 constructs 
 To characterize the unique roles of the TIMP-1 N- and C-terminal domains during 
development, I have performed a series of domain specific overexpression experiments. For 
this purpose, I generated full-length, N-terminal and C-terminal HA-tagged TIMP-1 mRNA 
constructs (T1FL, T1N and T1C, respectively), which were injected into newly fertilized X. 
laevis embryos (1 cell stage). Total RNA was collected from injected and control embryos 1 
day post-fertilization (stage 15), and RT-PCR analysis was used to verify levels of TIMP-1 
mRNA transcripts in injected embryos compared to controls (Fig. 3.2 A). Uninjected control 
embryos contained much lower levels of TIMP-1 mRNA compared to T1FL, T1N or T1C 
injected embryos, which showed relatively equal but elevated levels of TIMP-1 relative to Ef-
1α (loading control; Fig. 3.2 A).  By two days post-fertilization (stage 30), each HA-tagged 
TIMP-1 construct was still present and detectable on Western blot via HA antibody in 
injected embryos (Fig. 3.2 B), indicating that all constructs produced stable protein products. 
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Figure 3.2. Confirmation of full-length, N-terminal or C-terminal TIMP-1 constructs 
overexpressed in X. laevis embryos. 4 ng of mRNA coding for full-length (T1FL), N-
terminal (T1N) or C-terminal (T1C) TIMP-1 constructs was microinjected into X. laevis 
embryos at the 1 cell stage. (A) Overexpression of TIMP-1 mRNA as shown by RT-PCR 
analysis. mRNA was isolated from stage 15 embryos. Control (uninjected) embryos 
expressed TIMP-1 at very low levels. Primers specific to each construct were used to confirm 
mRNA levels of T1FL (678 bp), T1N (453 bp) and T1C (252 bp).  Ef-1α loading control is 
shown below (479 bp). (B) Levels of TIMP-1 constructs as detected by Western blot 
analysis. All constructs are HA-tagged.  Protein was isolated from stage 30 embryos. Anti-
HA antibodies were used to confirm expression of each construct at the protein level (T1FL 
= 26KDa, T1N = 18KDa, T1C = 12 KDa). No HA was detected in control uninjected 
embryos. β-actin was used as protein loading control.  
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3.3.3. Overexpression of full-length, N-terminal and C-terminal TIMP-1 constructs 
produced unique developmental phenotypes 
 Following injection of each TIMP-1 construct, embryos were monitored for gross 
morphological changes in development for 2 days post-fertilization (until developmental 
stage 30). Uninjected control embryos were morphologically normal (Fig. 3.3 A). By stage 
30 in development, embryos overexpressing full-length (T1FL) or N-terminal (T1N) TIMP-1 
displayed relatively normal anterior (head) development with posterior axis defects. T1FL 
and T1N injected embryos did, however, display a bent axis phenotype along with truncated 
anterior/posterior axes compared to controls (Fig. 3.3 B and C, respectively). Embryos 
overexpressing C-terminal TIMP-1 (T1C) also had truncated axis defects compared to 
controls, as well as other developmental abnormalities. Chiefly, T1C injections resulted in 
head defects, and failure of the neural tube to close (Fig. 3.3 D; see appendix C for additional 
images). Generally, overexpression of T1C resulted in more severe phenotypic consequences 
than overexpression of T1FL or T1N constructs.  
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Figure 3.3. Phenotypic effects of overexpression of full-length, N-terminal or C-terminal 
TIMP-1 constructs. Following injection, photographs were taken of representative embryos 
at stage 30. (A) Control (uninjected) embryos were phenotypically normal. Microinjection of 
T1FL (B) and T1N (C) constructs both resulted in normal anterior (head) development but 
truncated posterior axes. (D) Microinjection of T1C constructs resulted in lack of head 
structures, other head defects, and neural tube closure failure. Panel A magnification is lower 
than in B C and D. Actual size of all embryos is 1 mm in diameter. Images are of 
representative embryos where results were consistent in at least 3 independent sets of 
experiments, and a minimum of 100 embryos were injected and monitored for each replicate. 
See appendix C for additional images. 
 
500 µm 500 µm 
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3.3.4. Overexpression of full-length and C-terminal TIMP-1 resulted in increased 
embryonic lethality compared to overexpression of N-terminal TIMP-1  
 To compare and measure the effects of overexpressing full-length vs. N-terminal or 
C-terminal domain TIMP-1 during X. laevis development, T1FL, T1N and T1C injected 
embryos were monitored for 48 hours following fertilization, and the percent of normal 
embryos (embryos that were alive and morphologically normal) was determined and 
quantified at stage 15 (1 day post-fertilization) and stage 30 (2 days post-fertilization). More 
than 90% of control embryos, or embryos injected with GFP mRNA, developed normally 
during this time period (Fig. 3.4). Overexpression of all TIMP-1 constructs resulted in 
increased lethality compared to controls. By stage 15, all constructs resulted in an 
approximate 20% decrease in normal embryo numbers compared to controls (Fig. 3.4). By 
stage 30, 66% of T1N injected embryos developed normally, whereas T1FL and T1C 
constructs were slightly more detrimental, with only 58% and 55% normal development, 
respectively (Fig. 3.4).  
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Figure 3.4. Overexpression of all three TIMP-1 constructs led to abnormal development 
and death. Following injection of mRNA constructs at the 1 cell stage, embryos were scored 
for a normal (no visible defect) phenotype at stage 15 and 30. Dead and abnormal embryos 
were counted as containing morphological defects.  The graph shows the percentage of 
normal embryos following injection of GFP mRNA (GFP), or full-length (T1FL), N-terminal 
(T1N) or C-terminal (T1C) TIMP-1 mRNA constructs at the given stages. Control embryos 
are uninjected. Results are based on 3 independent sets of experiments, bars indicate SE. 
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3.3.5. Overexpression of full-length, N-terminal or C-terminal TIMP-1 constructs in X. 
laevis embryos altered expression of proteolytic genes 
 To examine the roles of full-length, N-terminal or C-terminal TIMP-1 in regulating 
ECM remodeling in vivo, I investigated the expression patterns of hallmark genes involved in 
regulating ECM proteolysis following microinjection with T1FL, T1N or T1C constructs into 
X. laevis embryos. mRNA was collected from embryos at stage 30 in development, as I had 
observed specific and unique morphological defects at this time point following injection of 
each construct (see Fig. 3.3). Semi-quantitative RT-PCR analysis, was used to assay for 
changes in mRNA levels of the MMP inhibitors TIMP-2, TIMP-3 and RECK, as well as the 
MMPs MMP-2, -9 and MT1-MMP. All of these genes have previously been shown to be 
important regulators of ECM remodeling during development (Hasebe, Hartman et al. 2007; 
Chandana, Maeda et al. 2010; Monsonego-Ornan, Kosonovsky et al. 2012; Nieuwesteeg, 
Walsh et al. 2012). mRNA levels were normalized to Ef-1α and compared to control 
(uninjected) embryos.  
 Overexpression of T1FL and T1C significantly decreased TIMP-2 mRNA relative to 
controls (Fig. 3.5 A, p < 0.05). This decrease was most significant following overexpression 
of TIC (p < 0.01); whereas, T1N did not significantly alter TIMP-2 compared to control 
embryos. Levels of TIMP-3 mRNA were not significantly altered compared to control 
embryos following treatment with of any of the TIMP-1 constructs (Fig. 3.5 B).  RECK 
expression was significantly decreased relative to controls following injection of T1FL (p < 
0.05) and T1C (p < 0.01, Fig. 3.5 C) constructs.  
 MMP-2 mRNA levels were significantly decreased compared to controls following 
overexpression of all constructs (T1FL, T1N and T1C; Fig. 3.6 A, p < 0.01). Following 
injection of T1C, MMP-9 mRNA was significantly decreased (Fig. 3.6 B, p < 0.05). No 
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significant change in MMP-9 mRNA levels was observed in embryos injected with T1FL or 
T1N constructs (Fig. 3.6). Similarly, levels of MT1-MMP mRNA were not altered relative to 
control embryos following overexpression of any TIMP-1 constructs (Fig. 3.6 C).    
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Figure 3.5. Effect of overexpression of full-length, N-terminal or C-terminal TIMP-1 on 
mRNA levels of MMP inhibitors. Semi-quantitative RT-PCR analysis was used to measure 
changes in mRNA levels of (A) TIMP-2, (B) TIMP-3 and (C) RECK at stage 30, following 
microinjection of 4 ng of TIMP-1 full-length (T1FL), N-terminal (T1N), or C-terminal (T1C) 
constructs into X. laevis embryos at the 1 cell stage. In each case mRNA levels were 
measured relative to Ef-1α. The results are presented as mean ±SE from 3 independent 
experiments. Asterisks represent a significant difference of * p < 0.05 and ** p < 0.01, all 
versus control (CONT; uninjected) embryos, as analyzed by one-way ANOVA and Dunnett’s 
multiple comparisons test. 
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Figure 3.6. Effect of overexpression of full-length, N-terminal or C-terminal TIMP-1 on 
mRNA levels of MMPs. Semi-quantitative RT-PCR analysis was used to measure changes 
in mRNA levels of (A) MMP-2, (B) MMP-9 and (C) MT1-MMP at stage 30, following 
microinjection of 4 ng of TIMP-1 full-length (T1FL), N-terminal (T1N), or C-terminal (T1C) 
constructs into X. laevis embryos at the 1 cell stage. In each case mRNA levels were 
measured relative to Ef-1α. The results are presented as mean ±SE from 3 independent 
experiments. Asterisks represent a significant difference of * p < 0.05 and ** p < 0.01, all 
versus control (CONT; uninjected) embryos, as analyzed by one-way ANOVA and Dunnett’s 
multiple comparisons test.  
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3.3.6. Overexpression of all TIMP-1 constructs decreased the amount of active MMP-2 
and -9 
 To further understand how the individual TIMP-1 domains affect the proteolytic 
network in vivo, gelatin zymography was used to measure changes in the amounts of active 
MMP-2 and -9 in T1FL, T1N or T1C injected embryos relative to control (uninjected) 
embryos.  Embryos injected with T1FL, T1N and T1C constructs showed significantly 
decreased levels of active MMP-2 relative to control embryos (Fig. 3.7 A, p < 0.01). 
Injection of all three TIMP constructs also resulted in significantly decreased levels of active 
MMP-9 relative to controls (Fig. 3.7 B, p < 0.01); however, interestingly, this trend was most 
pronounced following injection of the T1C construct.  
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Figure 3.7. Zymography demonstrated altered levels of active MMP-2 and MMP-9 
following overexpression of TIMP-1 constructs. Embryos were injected at the 1 cell stage 
with 4 ng of mRNA coding for full-length (T1FL), N-terminal (T1N) or C-terminal (T1C) 
constructs, and protein was isolated from stage 30 embryos. Gelatin zymography was used to 
measure changes in (A) MMP-2 and (B) MMP-9 activity. Zymogram (top) is representative 
of one experiment. Graphs represent quantification zymograms, and data is presented as 
mean ± SE from 3 independent experiments. ** p < 0.01, all versus control (CONT; 
uninjected) embryos, as analyzed by one-way ANOVA and Dunnett’s multiple comparisons 
test. 
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3.3.7. Only full-length and N-terminal TIMP-1 constructs directly inhibited MMP activity 
 To validate the MMP-inhibitory activity of the full-length and N-terminal TIMP-1 
constructs, and also to confirm that the C-terminal TIMP-1 construct could not directly 
inhibit MMPs, I performed reverse zymography. Reverse zymography is a modification of 
traditional zymography by incorporating gelatin into the gel matrix as well as conditioned 
media from cancer cells as a source of MMP-2 and -9 activity. Subsequently, the proteins of 
interest are separated within the gel by molecular weight. The gelatin is degraded by MMPs 
in the matrix, except for where inhibited by active TIMPs. TIMP activity is visualized as a 
dark band after staining with Coomassie Blue (Hawkes, Li et al. 2010), representing a 
protected band corresponding to the molecular weight of the active construct. Protein was 
isolated from injected stage 30 embryos, and analyzed for MMP-inhibitory activity 
corresponding to T1FL, T1N and T1C construct sizes. T1FL and T1N constructs showed 
MMP-inhibitory activity at the expected sizes of 26 KDa and 18 KDa, respectively (Fig. 3.8, 
white arrows), whereas the T1C construct was not able to inhibit MMPs at the expected size 
of 12 KDa (Fig. 3.8, black arrow).  Control embryos showed a faint band corresponding to 
endogenous TIMP-1 (26 KDa), which was upregulated in T1FL injected embryos (Fig. 3.8). 
Higher molecular weight bands are not indicative of TIMP activity, but represent proteins 
that are present at sufficiently high concentrations to be stained by Coomassie Blue, due to 
the large amount of yolk present in X. laevis embryos (Hawkes, Li et al. 2010). 
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Figure 3.8. Reverse zymography demonstrated full-length and N-terminal, but not C-
terminal TIMP-1, can directly inhibit MMP activity. Embryos were injected at the 1 cell 
stage with 4 ng of mRNA coding for full-length (T1FL), N-terminal (T1N) or C-terminal 
(T1C) TIMP-1 constructs, and protein was isolated from stage 30 embryos. MMP-inhibitory 
activity is represented by dark bands. White arrows indicate the location of the expected 
inhibitory bands corresponding to the T1FL (26 KDa) and T1N (18 KDa) constructs, 
respectively. A black arrow represents the position of the T1C (12 KDa) construct, which 
cannot inhibit MMP activity as demonstrated by the presence of a light band. Higher non-
specific molecular weight bands at the top of the gel help demonstrate equal protein loading. 
Such bands are not indicative of TIMP activity but are the result of high concentrations of 
proteins that stain deeply with Coomassie Blue. This is seen with many complex tissues (Van 
Wart and Birkedal-Hansen 1990) and is due to the very abundant yolk and other storage 
proteins that are found in the embryo. 
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3.4 Discussion 
  ECM remodeling is a key process involved in regulating tissue growth and 
morphogenesis during development. Maintaining the appropriate balance between MMPs 
and their inhibitors (TIMPs and RECK) is absolutely essential for normal development, and 
disruption of this balance leads to defects in neurulation, organogenesis and angiogenesis 
(Liotta, Steeg et al. 1991; Blelloch and Kimble 1999; Monsonego-Ornan, Kosonovsky et al. 
2012).  Our understanding of the regulation of this proteolytic network has been convoluted 
by the discovery that TIMP proteins have both MMP-inhibitory activity as well as MMP-
independent cell signaling activity (Lambert, Dasse et al. 2004). With recent research on 
TIMP C-terminal domains demonstrating their roles in apoptosis, cell proliferation, and cell 
migration pathways, the functions of the TIMP C-terminal domains are becoming 
increasingly studied in vitro (Hayakawa, Yamashita et al. 1992; Guedez, Stetler-Stevenson et 
al. 1998; Li, Fridman et al. 1999; Oh, Seo et al. 2004). At the present time there has been 
comparatively little research characterizing the roles of the N- and C-terminal TIMP domains 
in vivo, particularly as they pertain to development. My research has previously examined the 
specific functions of the N- and C-terminal domains of TIMP-2 and -3 during X. laevis 
development, and found that the two domains have unique functions when overexpressed 
individually in X. laevis embryos (Chapter 2) (Nieuwesteeg, Walsh et al. 2012). To date, 
there has been no comparison of the unique functions of TIMP-1 N- and C-terminal domains 
in a developmental context. Here I used mRNA overexpression to examine the role of full-
length TIMP-1 versus the roles of its individual N-terminal and C-terminal domains during 
early X. laevis development. 
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3.4.1. TIMP-1 N-terminal domains were more highly conserved with other vertebrates than 
their C-terminal domains 
 To examine whether the distinct functions of the two TIMP-1 domains are reflected 
in their evolutionary conservation, I identified and compared amino acid sequence identities 
of the X. laevis TIMP-1 N- and C-terminal domains to other known vertebrate TIMP-1 
sequences. I found that the TIMP-1 N-terminal domains were more highly conserved than 
their C-terminal domains among most species analyzed, with the exception of the large 
mammals, horse and cow, in which the C-terminal domains were more highly conserved 
(Fig. 3.1 A).  Since the catalytic domains of MMPs are highly conserved between species, it 
is not surprising that TIMP-1 N-terminal MMP-inhibitory domains are also well conserved 
(Van Wart and Birkedal-Hansen 1990). I have previously shown that the TIMP-2 N-terminal 
domains were also more highly conserved across species than their C-terminal domains, 
whereas for TIMP-3, I found the C-terminal domains were more highly conserved (Chapter 
2, sections 2.3.1. and 2.3.2.) (Nieuwesteeg, Walsh et al. 2012). My findings suggest TIMP-1 
may behave more like TIMP-2 than TIMP-3 with respect to MMP inhibition. Indeed, TIMP-
3 is unique in that it is a good inhibitor of the ADAM family of proteases (Rapti, Atkinson et 
al. 2008). Additionally, TIMP-3 is sequestered away from the cell surface, whereas TIMP-1 
and -2 function in a pericellular manner (Yu, Yu et al. 2000). While the TIMP-1 N-terminal 
domain is more conserved than the C-terminal domain, phylogenetic analysis of sequence 
divergence between vertebrate N- and C-terminal domains showed that the evolutionary 
patterns are different, suggesting that both domains evolved under unique selective pressures 
(Fig. 3.1 B and C). This suggests that functional roles of each domain are not the same.  
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3.4.2. Overexpression of the TIMP-1 C-terminal domain resulted in detrimental 
developmental defects 
 To examine differences in the in vivo roles of the TIMP-1 N- and C-terminal domains 
I generated and overexpressed full-length, N- and C-terminal TIMP-1 mRNA constructs in X. 
laevis embryos (T1Fl, T1N an T1C, respectively). Injection of embryos with T1C resulted in 
more embryonic death than injection with T1FL or T1N (Fig. 3.4).  Consistent with this 
observation, overexpression of T1C also resulted in more severe developmental defects in 
embryos at stage 30 in development, with these embryos showing head and neural tube 
defects, as well as truncated axes. In comparison, T1FL and T1N injected embryos showed 
normal head development but truncated anterior-posterior axes (Fig. 3.3), indicating that the 
TIMP-1 C-terminal domain may contribute to unique functions in development separate from 
the N-terminal domain. 
 
3.4.3. The TIMP-1 C-terminal domain altered the ECM proteolytic network independent of 
MMP inhibition  
 In order to further investigate the roles of the two TIMP-1 domains, RT-PCR analysis 
was used to examine changes in mRNA levels of associated genes known to be involved in 
the regulation of ECM remodeling. No changes were detected in levels of TIMP-3 or MT1-
MMP mRNA relative to control embryos, following injection with full-length, N-terminal or 
C-terminal TIMP-1. This is consistent with previous work, which showed that association of 
TIMP-1 with MT1-MMP is exceptionally poor (Hamze, Wei et al. 2007). In contrast, TIMP-
2 and RECK mRNA decreased compared to controls following injection of embryos with 
T1FL or T1C; however, these decreases were most significant with T1C (Fig. 3.5). This 
supports the concept that the C-terminal domain has the ability to regulate developmental 
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events independent from the N-terminal domain, presumably through cell surface receptor-
mediated signaling pathways.  
Similarly, overexpression of T1C resulted in the most marked decreases in amounts 
of MMP-2 and -9 mRNA compared to control embryos; although, in the case of MMP-2, 
ectopic expression of all three constructs significantly decreased MMP-2 mRNA (Fig. 3.6). 
These results were consistent with the zymography data, which showed the amounts of active 
MMP-2 and -9 proteins followed the same trends as the RT-PCR analysis (Fig. 3.7). 
Decreases in MMP-2 and -9 protein and mRNA may be partially due to a regulatory 
feedback mechanism in the proteolytic network which occurs from direct catalytic inhibition 
of MMPs by the N-terminal TIMP-1 domain, as T1N overexpression significantly decreased 
MMP-2 mRNA and MMP-2 protein compared to control embryos. My results suggest, 
however, that the C-terminal domain of TIMP-1 has the ability to regulate MMP mRNA and 
protein levels independent from the N-terminal domain. Reverse zymography using MMP-
conditioned media from Hs578t cells showed that TIC constructs cannot directly inhibit 
MMP activity (Fig. 3.8), yet overexpression of T1C resulted in the most significant decrease 
in MMP-9 mRNA as well as a pronounced decrease in MMP-9 protein compared to control 
embryos (Fig. 3.6 and 3.7). Although the mechanism of action of the TIMP-1 C-terminal 
domain is still unknown, TIMP-1 has previously been shown to bind to cell surface receptors 
on both fibroblasts and MCF-7 breast cancer cells, which resulted in translocation of TIMP-1 
into the cell (Zhao, Li et al. 1998; Hamze, Wei et al. 2007). Taken together with the 
emerging discoveries of new cell surface binding partners for TIMP-1, and its MMP-
independent roles in cell signaling (Stetler-Stevenson 2008), it is possible that the C-terminal 
domain of TIMP-1 may function to regulate expression of proteolytic genes through a 
signaling mechanism that is separate from the N-terminal domain MMP-inhibitory activity. 
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3.4.4. Concluding remarks 
In summary, this research characterized in vivo the unique role of the TIMP-1 C-
terminal domain.  In vitro studies have demonstrated new roles for the TIMP C-terminal 
domains in cell signaling.  Additionally, disease models have highlighted the emerging 
significance of the C-terminal TIMP domains in regulating the proteolytic network, as 
synthetic MMP inhibitors designed to mimic TIMP N-terminal domains failed as an anti-
cancer therapy to block metastasis associated with upregulated MMP activity (Brown 1998). 
Here I have shown for the first time in vivo that the TIMP-1 C-terminal domain has an 
independent role in regulating the proteolytic network during development, at a time when 
this network is both complex and tightly regulated. I have no direct evidence as to the 
mechanisms through which the individual ectopic domains are manifesting developmental 
anomalies; however, there is evidence that feedback is involved as disruption of the 
proteolytic network was compensated for in the embryo by changes in the levels of key 
genes.  Further, while there is no evidence that nascent TIMP-1 is cleaved into its individual 
domains, my research suggests that the functions of the TIMP-1 N- and C-terminal domains 
depend on the affinities of the individual domains for their binding partners, as well the 
stoichiometric levels of TIMP-1 relative to secreted MMPs and cell surface receptors. 
Further in vivo studies are needed to fully investigate whether there is preferential binding of 
either domain in the context of abundant active MMPs and/or cell surface receptors.    
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ANALYSIS OF THE EFFECTS OF TIMP-1, -2 AND -3 N- AND C-TERMINAL 
DOMAINS ON SIGNALING MARKERS DURING X. LAEVIS DEVELOPMENT 
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4.1 Introduction 
Although TIMPs were originally identified and characterized based on their abilities 
to bind to and inhibit MMPs, it is now acknowledged that TIMPs are multifunctional 
proteins, which can have pleiotropic effects on ECM remodeling and cell behavior. While the 
TIMP N-terminal domains have been shown to impede MMP activity in many cell types and 
model organisms, their C-terminal domains have demonstrated cell signaling activity in 
specific cell lines in vitro. Characterization of TIMP C-terminal domain function has been 
difficult as their roles in cell signaling vary, not only between the different TIMPs, but also 
depending on the cell line under study (Stetler-Stevenson 2008). The seemingly contradictory 
roles of TIMPs in up-regulating or down-regulating apoptosis and cell proliferation pathways 
indicates that TIMPs may have cell or tissue-specific roles, where TIMP function may 
depend on both the availability of cell surface receptors and the stoichiometry of free TIMPs 
and MMPs within the ECM.  
4.1.1. TIMPs in cell signaling 
As discussed in previous chapters, in vitro studies have linked TIMPs to induction or 
inhibition of apoptosis and cell proliferation pathways, as well as to upregulation of the cell 
surface MMP inhibitor, RECK. TIMP-1 in particular has been shown to inhibit apoptosis in 
Burkitt’s lymphoma cell lines, and this inhibition was demonstrated to occur through the 
TIMP-1 C-terminal domain binding to the CD63-β1-integrin complex in MCF10A cells 
(section 1.6.2) (Guedez, Stetler-Stevenson et al. 1998; Berditchevski and Odintsova 1999; 
Liu, Taube et al. 2005; Jung, Liu et al. 2006). TIMP-1 has also been shown to have both cell 
growth promoting and cell growth inhibiting activities in various cell lines, which are 
independent from N-terminal domain-mediated inhibition of MMPs (Bertaux, Hornebeck et 
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al. 1991; Hayakawa, Yamashita et al. 1992; Chesler, Golde et al. 1995; Taube, Liu et al. 
2006). Likewise, there are several conflicting reports in the literature regarding the role of 
TIMP-2 in mediating cell growth and apoptosis pathways. In the MCF-7 breast cancer cell 
line TIMP-2 had demonstrated cell growth promoting activity, which occurred through 
association of the TIMP-2 C-terminal domain with MT1-MMP on the cell surface to activate 
the MAPK pathway (section 1.6.2.) (D'Alessio, Ferrari et al. 2008). In contrast, TIMP-2 
inhibited cell growth through binding to α3β1 integrin receptors, leading to upregulation of 
the cyclin dependent kinase inhibitor p27kip1 in cultured human endothelial cells. 
Interestingly, this association also led to increased expression of RECK, and subsequently 
decreased cell migration (section 1.6.2.) (Oh, Seo et al. 2004; Seo, Li et al. 2006). The role of 
TIMP-2 in regulating apoptosis is also unclear, and varies between different cell types. 
Whereas TIMP-2 has been shown to suppress apoptosis in melanoma cells, in human T-
lymphocytes TIMP-2 promoted apoptosis (Valente, Fassina et al. 1998; Lim, Guedez et al. 
1999). 
 In contrast to TIMP-1 and -2, TIMP-3 is sequestered in the ECM and consequently, 
has limited direct ability to participate in cell surface signaling events (discussed in section 
1.6.2.) (Stetler-Stevenson 2008). However, as previously mentioned, TIMP-3 is a good 
inhibitor of ADAM family proteases, particularly ADAM-17 (also known as TACE (TNF-α 
converting enzyme)). ADAM-17 facilitates the shedding of transforming growth factor-α 
(TNF-α) as well as various cell surface receptors including FAS and TNF-related apoptosis 
inducing ligand receptor 1 (TRAIL-R1) (Pavloff, Staskus et al. 1992; Black 2002). Thus, 
although TIMP-3 has been associated with some cellular signaling pathways, particularly 
with changes in apoptosis, this activity is thought to occur indirectly as a result of ADAM 
inhibition, rather than as a result of direct signaling activity (Stetler-Stevenson 2008).  
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4.1.2. TIMPs in vivo 
In vivo, TIMP knockout mouse models display developmental deficiencies, 
demonstrating the importance of TIMPs in regulating normal development. In particular, 
TIMP-1 and -2 specifically, have been associated with defects in brain and neural 
development. TIMP-1 null mice had diminished neuronal development and impaired learning 
and memory (Jourquin, Tremblay et al. 2005; Chaillan, Rivera et al. 2006), while TIMP-2 
null mice showed decreased neurite outgrowth, delayed neuronal differentiation and 
considerable motor dysfunction (Perez-Martinez and Jaworski 2005; Jaworski, Soloway et al. 
2006), though the precise mechanisms through which these defects manifested remain 
unclear. In contrast, TIMP-3 null mice predominantly showed increased apoptosis in cells of 
the mammary glands, and defective alveolar and lung development (Fata, Leco et al. 2001; 
Leco, Waterhouse et al. 2001), both of which have been attributed to enhanced MMP activity 
(Brew and Nagase 2010). In X. laevis, ectopic expression of TIMP-3 has been associated 
with perturbation of head and neural structures (Pickard and Damjanovski 2004), a finding 
that I have corroborated using full-length and N-terminal domain TIMP-3 constructs (but not 
C-terminal TIMP-3), also indicating that the role of TIMP-3 in development is dependent on 
its MMP-inhibitory activities (Chapter 2) (Nieuwesteeg, Walsh et al. 2012).  
 
4.1.3. Experimental approach 
Due to the conflicting roles of the TIMP C-terminal domains in different cell lines in 
vitro, there is a need to further examine TIMP domain function in vivo to determine whether 
TIMP-mediated signaling activities are conserved between whole organisms and cell culture 
models. There is also a need to improve our understanding of how the activities of the two 
TIMP domains are balanced within the complex ECM proteolytic network in vivo. I have 
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previously shown that during development, the X. laevis TIMP-1 and -2 C-terminal domains 
can regulate MMP amounts and activity levels independent of N-terminal domain MMP-
inhibitory activity (Chapters 2 and 3), indicating a unique role for the TIMP C-terminal 
domains in regulating the stoichiometry of molecules within the ECM proteolytic network. 
TIMPs have been associated with apoptosis, cell proliferation, and migration (RECK) 
pathways in vitro, and as these pathways are all important regulators of developmental 
events, I wanted to investigate whether the TIMP C-terminal domains also have the ability to 
alter these pathways during development. As TIMP-1, -2 and -3 have all been linked to 
neural development in other in vivo studies, and my previous research has shown that 
overexpression of many of my TIMP constructs disrupted normal head and neural 
development (see sections 2.3.4., 2.3.5., and 3.3.3.), in this chapter I have specifically 
examined head histological sections of embryos injected with either full-length, N-terminal, 
or C-terminal domain TIMP-1, -2 or -3 constructs. Due to the severe nature of the 
developmental defects in many of the TIMP injected embryos, it was difficult to identify 
specific head structures. Accordingly, anterior sections from embryos at developmental stage 
30 (organogenesis) were examined using immunohistochemistry (IHC). Using IHC I assayed 
for changes in markers of cell proliferation and apoptosis, as well as for changes in RECK 
protein levels.  While analysis of changes in anterior expression could be used to confirm the 
known important neural and head roles played by TIMPs, a comparison of relative levels of 
signaling markers in specific tissues could not be compared between these deformed 
embryos. Therefore, I also collected whole embryo protein lysates from injected embryos and 
used Western blot analysis to quantify and compare changes in levels of proliferation and 
apoptosis markers, as well as in RECK protein levels. The purpose of this research was to 
compare the effects of the TIMP C-terminal domain constructs to their respective N-terminal 
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domains, and to demonstrate whether the TIMP C-terminal domains have any unique 
abilities to alter these signaling pathways in vivo. Specifically, changes in apoptosis were 
assayed using active caspase-3 antibody, proliferation via a phosho-histone-3 (PH3) 
antibody, and RECK protein levels using a RECK antibody. 
4.2 Materials and Methods 
4.2.1. Animals 
Adult X. laevis were purchased from Xenopus I Inc (Dexter, MI), and fertilized, 
reared and housed as described in section 2.2.2. 
 
4.2.2. Generation of TIMP constructs for microinjection  
Briefly, PCR was used to produce HA-tagged full-length, N-terminal and C-terminal 
domain constructs for TIMP-1, -2 and -3. Details regarding TIMP construct generation can 
be found in section 2.2.4. for TIMP-2 and -3, and section 3.2.4. for TIMP-1. 
 
4.2.3. Microinjection of TIMP-1, -2 and -3 mRNA constructs in X. laevis embryos 
 Fertilized embryos at the 1 cell stage were microinjected with TIMP-1, -2 or -3 full-
length, N-terminal or C-terminal domain mRNA constructs. Microinjections were preformed 
as previously described in sections 2.2.5. and 3.2.5. Embryos were monitored until 
developmental stage 30 (2 days post-fertilization). 
 
4.2.4. Protein preparations and Western blotting  
 Protein was extracted from stage 30 embryos injected with the various TIMP 
constructs, or uninjected control embryos. Protein extraction, quantification and Western 
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blotting were preformed from 10 pooled embryos from 3 independent experiments, as 
previously described in section 3.2.7. Primary antibodies used were RECK (H-300) (rabbit 
polyclonal, 1:200 dilution; Santa Cruz), p-Histone H3 (ser-10) (rabbit polyclonal, 1:200 
dilution; Santa Cruz), anti-active caspase-3 (rabbit polyclonal,1:500 dilution; Abcam), and 
anti-β-actin (C4) (mouse monoclonal, 1:1000 dilution; Santa Cruz). Secondary antibodies 
used were goat anti-rabbit HRP (1:5000 dilution; Life Technologies) or goat anti-mouse HRP 
(1:5000 dilution; Bio-Rad). Western blots were visualized and photographed using Bio-Rad 
Quantity One 4.4.0 software. Densitometry was performed using ImageJ software, where 
levels of PH3, RECK or caspase-3 were standardized to β-actin, and plotted as mean ± SE 
based on 3 independent experiments.  
 
4.2.5. Immunohistochemistry and fluorescence microscopy 
Stage 30 embryos injected with TIMP-1, -2 or -3 full-length, N-terminal or C-
terminal mRNA constructs, or control (uninjected) embryos were fixed for 2 hr at room 
temperature in 3.7% paraformaldehyde in 1X phosphate buffered saline (PBS). Fixed 
embryos were dehydrated in 70% ethanol and sectioned at the Molecular Pathology Core 
Facility in Robarts Research Institute (London, ON).  Embryos were embedded in paraffin, 
sectioned at a thickness of 6 µm, and mounted on glass slides. Slides were washed in xylene 
for 15 min to deparaffinize the sections, and then gradually rehydrated through a series of 5 
min washes in 100% ethanol, 90% ethanol + 10% PBST (1x phosphate-buffered saline + 
0.1% Triton-X (Sigma)), and 80% ethanol + 20% PBST, followed by two 5 min washes in 
100% PBST. Sections were blocked with 10% goat serum in 1X PBST for 45 min at room 
temperature. Note: For sections labeled with RECK antibody, 1X PBS was used in place of 
1X PBST for all washes described above. Immunostaining was performed by incubating 
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sections with primary antibodies against RECK (H-300) (rabbit polyclonal; Santa Cruz), p-
Histone H3 (ser-10) (rabbit polyclonal; Santa Cruz), or anti-active caspase-3 (rabbit 
polyclonal; Abcam). All primary antibodies were used at a 1:50 dilution and incubated 
overnight at 4 °C. Caspase-3 and PH3 antibodies were diluted in 2% BSA in PBST, and 
RECK antibody was diluted in 2% BSA in PBS. Slides were washed 3 times for 5 min in 
PBST (PBS for RECK labeled sections), and incubated for with secondary antibody at a 
1:200 dilution for 2 hr at room temperature (Alexa Fluor® 488 Goat Anti-Rabbit IgG; Life 
Technologies). Secondary antibodies were diluted in 2% BSA in PBST for caspase-3 and 
PH3 labeled sections, and in 2% BSA in PBS for RECK labeled sections. Sections were 
washed 3 times for 5 min in PBST (PBS for RECK labeled sections), followed by one 5 min 
wash in double-distilled H2O. All sections were mounted and counterstained with ProLong® 
Gold antifade reagent containing 4', 6-diamidino-2-phenylindole (DAPI) (Life 
Technologies). Anterior head portions of embryos in a 200X field of view were visualized 
and photographed using a Leica DMI600 B microscope and Leica MM AF 1.4.0 software. 
ImageJ software was used to measure PH3, caspase-3 or RECK signal relative to DAPI 
(indicative of total number of cells) in anterior head sections of injected embryos all the same 
magnification (200X). Immunohistochemistry and quantification of fluorescence are 
representative measurements based on 1 image, with 4 consistent technical repeats for each 
embryo imaged. Results were consistent and observed in no less than 2 embryos.  
 
4.2.6. Statistical Analysis 
All statistical analysis was performed using the IBM SPSS Statistic 19 program. 
Results were presented as mean ± SE. Western blot data were log transformed (Log10) to 
achieve normal distribution. Statistical significance was determined using One Way ANOVA 
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variance analysis followed Dunnett’s multiple comparisons test. Differences were considered 
statistically significant when p < 0.05.  
 
4.3 Results 
4.3.1. Overexpression of full-length, N-terminal and C-terminal TIMP constructs did not 
alter PH3 levels in X. laevis embryo sections or protein lysates 
PH3 was used as an indicator of cell proliferation in order to characterize the roles of 
the TIMP-1, -2 and -3 N- and C-terminal domains in regulating this pathway during 
development. Immunostaining of anterior head sections from stage 30 embryos showed that 
overexpression of full-length, N-terminal or C-terminal domain TIMP-1 resulted in relatively 
equal levels of PH3 compared to control embryos (Fig. 4.1 A). Western blot analysis from 
whole embryo protein lysates confirmed this trend, as changes in PH3 levels were not 
significantly different from control embryos following injection of any of the TIMP-1 
constructs (Fig. 4.1 B). Similarly, overexpression of TIMP-2 full-length, N-terminal or C-
terminal domain constructs did not alter levels of PH3 relative to control embryos. Although 
the T2N construct resulted in slightly decreased levels of PH3 as examined by IHC (Fig. 4.2 
A), this decrease was statistically insignificant when quantified via Western blot (Fig. 4.2. B, 
p > 0.05). Additionally, none of the TIMP-3 constructs altered PH3 levels compared to 
control (uninjected) embryos (Fig. 4.3 A and B), suggesting that TIMPs may not significantly 
impact proliferation in X. laevis embryos.  
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Figure 4.1. TIMP-1 N- or C-terminal domains did not alter PH3 levels in X. laevis 
embryos. Embryos were injected at the 1 cell stage with 4 ng of either TIMP-1 full-length 
(T1FL), N-terminal domain (T1N) or C-terminal domain (T1C) mRNA constructs. (A) 
Anterior sections from stage 30 embryos (200X magnification) were analyzed for changes in 
PH3 (green) as an indicator of cell proliferation. The level of PH3 relative to DAPI (blue) 
fluorescence levels was measured for each section (ratio is Y-axis) and depicted graphically 
(black bars). (B) Western blot analysis was performed to measure changes in PH3 levels 
from whole embryo protein lysates. PH3 levels were measured relative to β-actin. Results are 
displayed as mean ± SE from 3 independent experiments. No significant changes in PH3 
levels relative to control uninjected (CONT) embryos were observed following 
overexpression of any TIMP-1 constructs, as analyzed by one-way ANOVA and Dunnett’s 
multiple comparisons test (p > 0.05). 
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Figure 4.2. TIMP-2 N- or C-terminal domains did not alter PH3 levels in X. laevis 
embryos. Embryos were injected at the 1 cell stage with 4 ng of either TIMP-2 full-length 
(T2FL), N-terminal domain (T2N) or C-terminal domain (T2C) mRNA constructs. (A) 
Anterior sections from stage 30 embryos (200X magnification) were analyzed for changes in 
PH3 (green) as an indicator of cell proliferation. The level of PH3 relative to DAPI (blue) 
fluorescence levels was measured for each section (ratio is Y-axis) and depicted graphically 
(black bars). (B) Western blot analysis measured changes in PH3 levels from whole embryo 
protein lysates. PH3 levels were measured relative to β-actin. Results are displayed as mean 
± SE from 3 independent experiments. No significant changes in PH3 levels relative to 
control uninjected (CONT) embryos were observed following overexpression of any TIMP-2 
constructs, as analyzed by one-way ANOVA and Dunnett’s multiple comparisons test (p > 
0.05). 
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Figure 4.3. TIMP-3 N- or C-terminal domains did not alter PH3 levels in X. laevis 
embryos. Embryos were injected at the 1 cell stage with 4 ng of either TIMP-3 full-length 
(T3FL), N-terminal domain (T3N) or C-terminal domain (T3C) mRNA constructs. (A) 
Anterior sections from stage 30 embryos (200X magnification) were analyzed for changes in 
PH3 (green) as an indicator of cell proliferation. The level of PH3 relative to DAPI (blue) 
fluorescence levels was measured for each section (ratio is Y-axis) and depicted graphically 
(black bars). (B) Western blot analysis measured changes in PH3 levels from whole embryo 
protein lysates. PH3 levels were measured relative to β-actin. Results are displayed as mean 
± SE form 3 independent experiments. No significant changes in PH3 relative to control 
uninjected (CONT) embryos were observed following overexpression of any TIMP-3 
constructs, as analyzed by one-way ANOVA and Dunnett’s multiple comparisons test (p > 
0.05). 
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4.3.2. Overexpression of full-length and C-terminal TIMP-1 constructs increased active 
caspase-3 levels in X. laevis embryos 
Active caspase-3 was used as an indicator of apoptosis to measure differences in the 
abilities of TIMP-1, -2 or -3 full-length, N- or C-terminal domain constructs to alter this 
pathway during development. Immunohistochemical examination of anterior head sections 
from stage 30 embryos demonstrated increased caspase-3 levels following overexpression of 
T1FL and T1C constructs (Fig. 4.4 A). These increases were confirmed as significant 
through Western blot analysis from whole embryo protein lysates at the same developmental 
stage (Fig. 4.4 B, p < 0.05). In contrast, quantification of caspase-3 levels via Western blot 
analysis demonstrated that none of the TIMP-2 constructs significantly altered caspase-3 
levels relative to control embryos (Fig. 4.5 B); however, the trend was toward the increase 
following overexpression of T2FL and T2C constructs in both IHC and Western blot 
analyses (Fig. 4.5 A and B). Similarly, overexpression of TIMP-3 constructs did not result in 
significantly altered caspase-3 levels compared to control embryos (Fig. 4.6 A and B).  
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Figure 4.4. Overexpression of TIMP-1 full-length and C-terminal domain constructs 
increased active caspase-3 levels in X. laevis embryos. Embryos were injected at the 1 cell 
stage with 4 ng of either TIMP-1 full-length (T1FL), N-terminal domain (T1N) or C-terminal 
domain (T1C) mRNA constructs. (A) Anterior sections from stage 30 embryos (200X 
magnification) were analyzed for changes in active caspase-3 (green) as an indicator of cell 
death. The level of caspase-3 relative to DAPI (blue) fluorescence levels was measured for 
each section (ratio is Y-axis) and depicted graphically (black bars). (B) Western blot analysis 
measured changes in caspase-3 levels from whole embryo protein lysates. Caspase-3 levels 
were measured relative to β-actin. Results are displayed as mean ± SE from 3 independent 
experiments. TIFL and T1C constructs significantly increased caspase-3 levels relative to 
control uninjected (CONT) embryos, as analyzed by one-way ANOVA and Dunnett’s 
multiple comparisons test *(p < 0.05). 
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Figure 4.5. Overexpression of TIMP-2 constructs did not alter active caspase-3 levels in 
X. laevis embryos. Embryos were injected at the 1 cell stage with 4 ng of either TIMP-2 full-
length (T2FL), N-terminal domain (T2N) or C-terminal domain (T2C) mRNA constructs. 
(A) Anterior sections from stage 30 embryos (200X magnification) were analyzed for 
changes in active caspase-3 (green) as an indicator of cell death. The level of caspase-3 
relative to DAPI (blue) fluorescence levels was measured for each section (ratio is Y-axis) 
and depicted graphically (black bars). (B) Western blot analysis measured changes in 
caspase-3 levels from whole embryo protein lysates. Caspase-3 levels were measured relative 
to β-actin. Results are displayed as mean ± SE from 3 independent experiments. TIMP-2 
constructs did not significantly alter caspase-3 levels relative to control uninjected (CONT) 
embryos, as analyzed by one-way ANOVA and Dunnett’s multiple comparisons test (p > 
0.05). 
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Figure 4.6. Overexpression of TIMP-3 constructs did not alter active caspase-3 levels in 
X. laevis embryos. Embryos were injected at the 1 cell stage with 4 ng of either TIMP-3 full-
length (T3FL), N-terminal domain (T3N) or C-terminal domain (T3C) mRNA constructs. 
(A) Anterior sections from stage 30 embryos (200X magnification) were analyzed for 
changes in active caspase-3 (green) as an indicator of cell death. The level of caspase-3 
relative to DAPI (blue) fluorescence levels was measured for each section (ratio is Y-axis) 
and depicted graphically (black bars). (B) Western blot analysis measured changes in 
caspase-3 levels from whole embryo protein lysates. Caspase-3 levels were measured relative 
to β-actin. Results are displayed as mean ± SE from 3 independent experiments. TIMP-3 
constructs did not significantly alter caspase-3 levels relative to control uninjected (CONT) 
embryos, as analyzed by one-way ANOVA and Dunnett’s multiple comparisons test (p > 
0.05). 
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4.3.3. Overexpression TIMP constructs altered RECK levels in X. laevis embryos 
To examine whether any of the TIMP domains had the ability to regulate RECK 
protein levels during development, changes in RECK levels were analyzed following 
overexpression of full-length, N-, and C-terminal domain constructs in X. laevis embryos. All 
changes were confirmed at both the IHC and Western blot level. Western blot analysis from 
stage 30 embryos showed that RECK expression was significantly increased following 
overexpression of TIFL and T1C constructs (Fig. 4.7 B, p < 0.05). In contrast, whereas 
overexpression of full-length and N-terminal domain TIMP-2 did not significantly alter 
RECK levels, the T2C construct resulted in decreased levels of RECK relative to control 
embryos that were detectable by IHC (Fig. 4.8 A) and confirmed as significant by Western 
blot (Fig. 4.8 B, p < 0.05). Additionally, while the TIMP-3 full-length and C-terminal domain 
constructs did not result in changes in RECK compared to controls, the T3N construct 
significantly decreased RECK levels compared to controls. Again, this decrease was detected 
by both IHC and Western blot analysis (Fig. 4.9 A and B, p < 0.05). !!!!!!!!!!!!!!!!!
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Figure 4.7. Overexpression of TIMP-1 full-length and C-terminal domain constructs 
increased RECK in X. laevis embryos. Embryos were injected at the 1 cell stage with 4 ng 
of either TIMP-1 full-length (T1FL), N-terminal domain (T1N) or C-terminal domain (T1C) 
mRNA constructs. (A) Anterior sections from stage 30 embryos (200X magnification) were 
analyzed for changes in RECK expression (green). The level of RECK relative to DAPI 
(blue) fluorescence levels was measured for each section (ratio is Y-axis) and depicted 
graphically (black bars). (B) Western blot analysis measured changes in RECK levels from 
whole embryo protein lysates. RECK levels were measured relative to β-actin. Results are 
displayed as mean ± SE from 3 independent experiments. TIFL and T1C constructs 
significantly increased RECK relative to control uninjected (CONT) embryos, as analyzed by 
one-way ANOVA and Dunnett’s multiple comparisons test *(p < 0.05). 
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Figure 4.8. Overexpression of the TIMP-2 C-terminal domain construct decreased 
RECK in X. laevis embryos. Embryos were injected at the 1 cell stage with 4 ng of either 
TIMP-2 full-length (T2FL), N-terminal domain (T2N) or C-terminal domain (T2C) mRNA 
constructs. (A) Anterior sections from stage 30 embryos (200X magnification) were analyzed 
for changes in RECK expression (green). The level of RECK relative to DAPI (blue) 
fluorescence levels was measured for each section (ratio is Y-axis) and depicted graphically 
(black bars). (B) Western blot analysis measured changes in RECK levels from whole 
embryo protein lysates. RECK levels were measured relative to β-actin. Results are displayed 
as mean ± SE from 3 independent experiments. The T2C construct significantly decreased 
RECK levels relative to control uninjected (CONT) embryos, as analyzed by one-way 
ANOVA and Dunnett’s multiple comparisons test *(p < 0.05). 
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Figure 4.9. Overexpression of the TIMP-3 N-terminal domain construct decreased 
RECK in X. laevis embryos. Embryos were injected at the 1 cell stage with 4 ng of either 
TIMP-3 full-length (T3FL), N-terminal domain (T3N) or C-terminal domain (T3C) mRNA 
constructs. (A) Anterior sections from stage 30 embryos (200X magnification) were analyzed 
for changes in RECK expression (green). The level of RECK relative to DAPI (blue) 
fluorescence levels was measured for each section (ratio is Y-axis) and depicted graphically 
(black bars). (B) Western blot analysis measured changes in RECK levels from whole 
embryo protein lysates. RECK levels were measured relative to β-actin. Results are displayed 
as mean ± SE from 3 independent experiments. The T3N construct significantly decreased 
RECK levels relative to control uninjected (CONT) embryos, as analyzed by one-way 
ANOVA and Dunnett’s multiple comparisons test *(p < 0.05). 
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4.4 Discussion 
I have previously shown that overexpression of all TIMP constructs, with the 
exception of the TIMP-3 C-terminal domain, resulted in severe developmental defects, 
including head, neural tube and axis defects, and that the TIMP-1 and -2 C-terminal domains 
altered MMP levels independent of MMP inhibition (see Chapter 2 and 3). As the TIMP-1 
and -2 C-terminal domains have been shown to regulate cell proliferation and apoptosis 
pathways in vitro, I wanted to investigate whether TIMPs may also contribute to cell 
signaling in vivo. In order to understand whether the TIMP C-terminal domains also have 
unique abilities to contribute to regulation of signaling pathways during development, I 
overexpressed TIMP-1, -2 or -3 full-length, N-terminal and C-terminal domain constructs in 
X. laevis embryos, and examined changes in levels of PH3 as an indicator of cell 
proliferation and active caspase-3 as a indicator of apoptosis. Additionally, I examined 
changes in RECK levels, as the TIMP-2 C-terminal domain has previously been shown to 
increase RECK expression in cultured human endothelial cells (Oh, Seo et al. 2004). PH3, 
caspase-3 and RECK were examined using IHC and Western blot. Due to the nature of the 
severe developmental defects resulting from overexpression of TIMP constructs, 
developmental landmarks were difficult to identify, and changes in localization could not be 
observed by IHC. Accordingly, the levels of PH3, caspase-3 and RECK were examined in 
anterior head sections from injected and control embryos and measured relative to DAPI. 
Western blot analysis using whole embryo protein lysates was used to corroborate trends 
observed in IHC and also quantify changes in the levels PH3, caspase-3 and RECK in stage 
30 embryos. 
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4.4.1. Ectopic expression of TIMP constructs did not alter cell proliferation in X. laevis 
embryos 
 Overexpression of TIMP-1, -2 or -3 full-length, N-terminal or C-terminal domain 
constructs did not result in significantly altered cell proliferation in X. laevis embryos, as 
indicated by changes in the levels of PH3. Although modest decreases in the levels of PH3 
relative to DAPI were observed in some embryo sections using IHC, these decreases were 
deemed insignificant by Western blot analysis from whole embryo protein lysates (Fig. 4.1, 
4.2 and 4.3). Interestingly, even the C-terminal domain constructs of TIMP-1 and -2 did not 
significantly alter proliferation relative to control embryos, indicating that there may be no 
direct or indirect roles for TIMPs in regulating this pathway during X. laevis development. 
Both the TIMP-1 and -2 C-terminal domains have been demonstrated in various cancer and 
fibroblast cell lines to either promote or inhibit cell proliferation (reviewed in Stetler-
Stevenson 2008), however, these experiments were performed using homogenous 
populations of differentiated cells. Although TIMPs may impact cell proliferation pathways 
through C-terminal domain-mediated cell signaling events in differentiated cell lines in 
culture, this mechanism may not be maintained in undifferentiated cells in embryos. 
Pluripotent or multipotent cells in the embryo are subject to distinct regulatory parameters, 
where TIMPs may not have the ability to alter proliferation. Although it is possible that small 
populations of cells in the embryo may be sensitive to TIMP-mediated changes in 
proliferation, these changes were not reflected in the whole embryo, at least as demonstrated 
by PH3 assays. A more careful analysis of localized changes in proliferation must be carried 
out to conclusively rule out a role for TIMPs regulating proliferation pathways during 
development. 
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4.4.2. The TIMP-1 C-terminal domain increased active caspase-3 in X. laevis embryos 
To investigate whether any of the X. laevis TIMPs had the ability to alter cell death 
during development (particulary through their C-terminal domains), I examined changes in 
active caspase-3 as an indicator of apoptosis, following overexpression of each of my TIMP 
constructs. The TIMP-1 full-length and C-terminal domain constructs significantly increased 
caspase-3 levels relative to control embryos (Fig. 4.4.). As the C-terminal domain construct 
has no MMP-inhibitory activity (see section 3.3.7.), this data suggests that changes in 
apoptosis are mediated by a C-terminal domain-specific mechanism, presumably cell 
signaling. While the TIMP-1 C-terminal domain has been linked to changes in apoptosis in 
both human lymphoma and mammary epithelia cell lines, these in vitro studies are associated 
with suppression of apoptosis, rather than the increase in apoptosis observed here (Guedez, 
Stetler-Stevenson et al. 1998; Berditchevski and Odintsova 1999; Li, Fridman et al. 1999; 
Guedez, Mansoor et al. 2001; Jung, Liu et al. 2006).  Although the importance of the TIMP-1 
C-terminal domain in regulating caspase-3 levels seems to be maintained in X. laevis, the 
effects of this protein may be different during development. This may be due to the fact that 
the embryo consists of a heterogeneous population of differentiating cells, where cell fate 
decisions are mediated in a highly complex manner, in contrast to the homogeneous 
populations of differentiated cells used in in vitro studies. Nevertheless, the role of TIMP-1 
in regulating amount of active caspase-3 during X. laevis development seems to be specific to 
the TIMP-1 C-terminal domain, as only the T1C and T1FL constructs (which contain a 
functional C-terminus) increased apoptosis. Furthermore, none of the TIMP-2 or -3 
constructs resulted in significantly altered levels of caspase-3 relative to control embryos, 
demonstrating that this effect is unique to TIMP-1. 
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Though a similar trend was observed following overexpression of T2FL and T2C 
constructs (Fig. 4.5), the resultant increases in caspase-3 were not significant compared to 
controls, indicating the TIMP-2 C-terminal domain may not play an important role in 
regulating this pathway during development. With only two conflicting reports in the 
literature regarding the effect of TIMP-2 on apoptosis (Valente, Fassina et al. 1998; Lim, 
Guedez et al. 1999), it is possible that TIMP-2 is simply not an important regulatory factor 
for this pathway. Additionally, while overexpression of the TIMP-3 constructs did not 
significantly alter caspase-3 levels relative to control embryos, modest increases in levels of 
caspase-3 were detected following overexpression of T3FL and T3N (but not T3C) 
constructs by IHC analysis, and these trends were mirrored by Western blot analysis (Fig. 
4.6). This is consistent with reports in the literature, which indicate that TIMP-3 may 
indirectly alter apoptosis through regulation of MMP and ADAM activity (Stetler-Stevenson 
2008). The TIMP-3 C-domain, which has no inherent MMP-inhibitory (or signaling) activity, 
did not follow this trend. 
 
4.4.3. The TIMP-1 and -2 C-terminal domains had opposing effects on RECK protein 
levels in X. laevis embryos 
RECK is a potent cell surface inhibitor of MMPs, thus, alterations in RECK 
expression may have considerable effects on cell migration during embryogenesis. As TIMP-
2 has previously been demonstrated to increase RECK expression in vitro (Oh, Seo et al. 
2004), here I investigated whether the X. laevis TIMPs or their individual domains may 
contribute to regulation of RECK expression in vivo, during development. Intriguingly, the 
TIMP-1 full-length and C-terminal domain constructs resulted in significantly increased 
levels of RECK protein when quantified using Western blot analysis (Fig.  4.7 B). The T1N 
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construct, which only functions in inhibition of MMP activity, did not result in changes in 
RECK expression relative to control embryos. Thus, this data suggests that the observed 
increases in RECK following overexpression of T1FL and T1C constructs are due to a C-
terminal domain specific mechanism. No previous reports have linked the TIMP-1 C-
terminal domain to a particular cell signaling pathway involved in the regulation of RECK 
expression; however, to date there has been limited research investigating TIMP-1-mediated 
regulation of RECK and other components of the ECM proteolytic network.  
Following overexpression of TIMP-2 full-length, N-, and C-terminal domain 
constructs, I found that only the T2C construct significantly decreased RECK expression 
relative to controls, whereas the T2FL and T2N constructs did not (Fig. 4.8). This finding is 
in contrast to the report by Oh et al. (2004), which showed that the TIMP-2 C-terminal 
domain increased RECK expression through binding to α3β1 integrin receptors on the 
surface of human microvascular endothelial cells. As the effect of TIMP-2 on regulation of 
RECK expression has currently only been examined using cultured human endothelial cells, 
it is possible that TIMP-2 may have varying effects on RECK expression, or may alter RECK 
expression through different pathways, depending on the requirements of different tissues 
and organisms. My research, however, demonstrated that TIMP-2 has the ability to alter 
RECK through its C-terminal domain, independent of MMP inhibition, during X. laevis 
development. 
 In contrast, overexpression of full-length and C-terminal domain TIMP-3 did not 
alter RECK relative to control embryos, indicating that the TIMP-3 C-terminal domain does 
not participate in signaling events that regulate RECK expression in X. laevis embryos. The 
T3N construct, however, did result in significantly decreased RECK levels relative to control 
embryos when analyzed by Western blot. As the TIMP N-terminal domains are involved in 
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MMP inhibition, and have not been associated with direct signaling activity, it is unlikely 
that the T3N construct decreased RECK expression through a direct signaling mechanism. 
Rather, the explanation may be simply due to the stoichiometry of MMP inhibitors within the 
ECM. Under normal conditions, full-length TIMP-3 is sequestered in the ECM away from 
the cell surface, a function that is mediated by its C-terminal domain (Yu, Yu et al. 2000), 
Thus, whereas the T3FL and T3C constructs may remain bound to the ECM, this ability 
would be impaired with the T3N construct. The T3N construct is free to act pericellularly, 
and therefore, may result in feedback to the cell to downregulate expression of other MMP 
inhibitors, like RECK. 
4.4.4. Concluding remarks 
This research is the first detailed comparison of the unique functions of the TIMP N- 
and C-terminal domains in vivo. Although a more thorough analysis is needed to identify 
binding partners and receptors for the TIMP C-terminal domains in vivo, I have shown for 
the first time that the TIMP-1 and -2 C-terminal domains have the ability to influence cell 
signaling pathways in X. laevis embryos. This research indicates that TIMPs may be 
important not only for mediating MMP activity during development, but also for regulating 
cell signaling pathways that influence apoptosis and cell migration, through RECK. 
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5.1 General Overview 
5.1.1. Context and significance of this research 
In recent years, the complexity underlying ECM dynamics has become apparent, as 
research has demonstrated the importance of maintaining the appropriate balance between 
ECM proteases and inhibitors in both development and disease. Not only is the balance 
between MMPs and TIMPs important for facilitating cell migration during development and 
metastasis (Liotta, Steeg et al. 1991; Blelloch and Kimble 1999), but TIMP-mediated 
inhibition of MMPs can also indirectly influence cell behavior by altering the availability and 
activity of secreted signaling molecules within the ECM (Brew and Nagase 2010). It has also 
become evident that TIMPs themselves may be important determinants of cell fate, as in 
vitro studies have shown that TIMP initiated cell signaling cascades can have significant 
consequences on apoptosis, cell migration, and cell proliferation pathways (Stetler-Stevenson 
2008; Brew and Nagase 2010). Due to the multifaceted roles of both MMPs and TIMPs, 
analysis of the functions of, and interactions between, ECM molecules has become 
exceedingly complex, particularly in vivo, where TIMP and MMP activities may be altered 
by the presence and relative abundance of different ECM components. To my knowledge, 
there have been no previous studies that have examined and compared the unique roles of the 
different TIMP N-terminal MMP-inhibitory and C-terminal cell-signaling domains in vivo. 
The research presented in this thesis is the first comprehensive comparison of the individual 
TIMP domains in vivo, as well as the first examination of TIMP domain functions as they 
pertain to development. 
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5.1.2. Research summary and general conclusions 
The overall goal of this research was to investigate in isolation the N- and C-terminal 
domains of all three X. laevis TIMPs during development, and to compare the effects of 
overexpression of the individual domains between the different TIMPs, as well as with their 
full-length counterparts. By using a series of domain-specific overexpression experiments 
and assays for: 1) gross morphological changes in development, 2) changes in the mRNA 
levels of ECM genes, 3) changes in the levels of active ECM proteases, and 4) changes in 
indicators of cell signaling pathways, I have performed a comprehensive comparison of 
TIMP domain function during X. laevis development. In general, my hypothesis was that 
overexpression of the TIMP N-terminal domains would have more similar effects on 
development, as inhibition of MMPs is a function common to all TIMPs; whereas, 
overexpression of the TIMP C-terminal domains would have varying effects on development, 
depending on their distinct abilities to participate in cell surface signaling events. Indeed, I 
have demonstrated that the TIMP-1 and -2 C-terminal domains have unique abilities to 
contribute to development that are mirrored following overexpression of the full-length 
construct. This research used C-terminal domain TIMP constructs to demonstrate in vivo the 
MMP-independent effects of TIMPs (that can be attributed to direct cell signaling functions) 
vs. the changes in development that arise due to TIMP inhibition of target proteases (through 
their N-terminal domains). 
 
5.2 Contributions to the Current Knowledge of ECM Dynamics During Development 
5.2.1. Identification and characterization of X. laevis TIMPs 
At the time this research was started, only X. laevis TIMP-2 and -3 genes had been 
identified. One of the firsts tasks I was faced with when beginning this project was to identify 
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and clone TIMP-1 and/or TIMP-4. As mentioned in section 1.3, while four TIMPs are present 
in mammals, many vertebrates do not express orthologs of all four TIMPs (Murphy 2011). 
Using database searches, I identified an unannotated X. laevis clone (AAI41767.1), which 
was highly homologous with other known TIMP-1 sequences at the amino acid level. 
Presently, there is no TIMP-4 in X. laevis based on available sequence data. It is possible that 
a TIMP-4 sequence may still be discovered as the sequencing of the X. laevis genome is still 
underway. However, Xenopus tropicalis, a closely related species to X. laevis, has been fully 
sequenced. Although a TIMP-1 ortholog has been identified, no TIMP-4 sequence has been 
discovered in X. tropicalis. In mammals, TIMP-4 has the most selective and restricted pattern 
of localization, with expression primarily in brain and heart (Baker, Edwards et al. 2002; 
Nuttall, Sampieri et al. 2004). Structurally, human TIMP-4 is most similar to TIMP-2 
(Melendez-Zajgla, Del Pozo et al. 2008), though studies suggest that the signaling 
capabilities of TIMP-4 are most similar to those of TIMP-1 (Stetler-Stevenson 2008). It is 
possible that the functions of TIMP-4 may be redundant with those of the other TIMPs, thus, 
some lower vertebrates such as frog may not contain TIMP-4 along with TIMP-1 or -2. 
Indeed, the fish Takifugu rubripes expresses TIMP-2, -3 and -4 but not TIMP-1, whereas 
insects such as Drosophila melanogaster express only one TIMP (Brew, Dinakarpandian et 
al. 2000; Tsukamoto, Yokoyama et al. 2006; Tsukamoto, Yokoyama et al. 2007; Brew and 
Nagase 2010).  
Amino acid sequence comparison of the three X. laevis TIMPs compared with those 
from other known full-length vertebrate and invertebrate species revealed that the N-terminal 
domains of TIMP-1 and -2 were more highly conserved than their C-terminal domains. This 
was expected, as the N-terminal domains are involved in the similar function of MMP 
inhibition, whereas the C-terminal domains of TIMP-1 and -2 have variable roles in cell 
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signaling that depend on cell and tissue type (Stetler-Stevenson 2008). The signaling 
functions of the C-terminal domains likely also vary between species; however, to date TIMP 
C-terminal domain function has only been examined in human, mouse and rat cell lines. 
Phylogenetic analysis of TIMP-1, -2 and -3 N- and C-terminal domains with those of other 
known species showed that for TIMP-1 and -3, the N- and C-terminal domains diverged 
under different selective pressures, whereas for TIMP-2 the two domains evolved in a 
concomitant manner. This study, however, was limited by the number of available annotated 
TIMP sequences, particularly from non-mammalian and invertebrate species. A broader 
study with more diverse species, as well as additional analysis of TIMP receptors is needed 
to truly determine if TIMP C-terminal domains evolved in parallel with changes in specific 
receptors and/or signaling pathways. 
 
5.2.2. TIMP C-terminal domains contribute to regulation of development in an MMP-
independent manner 
 TIMPs have long been acknowledged for their roles in MMP inhibition that are 
needed for regulation of developmental events involving cell migration. With the emerging 
signaling properties of TIMPs in cell migration, proliferation and apoptosis pathways, it was 
important to re-examine TIMP function in vivo, as these cell signaling pathways are not only 
important in regulation of cancer progression, but also in the regulation of development. The 
stoichiometry between MMPs, TIMPs, secreted signaling molecules, and cell surface 
receptors are important determinants of TIMP function. By disrupting this stoichiometry 
through overexpression of my TIMP constructs in early stage embryos, I have revealed for 
the first time in vivo that the TIMP C-terminal domains can contribute to development using 
an MMP-independent mechanism.  
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Specifically, I have shown that overexpression of the TIMP-1 and -2 C-terminal 
domains led to distinct developmental defects and large amounts of embryonic death. These 
developmental defects were linked to changes in MMP expression and activity levels, as well 
as to specific changes in signaling markers that were also observed following overexpression 
of the full-length constructs, but not with the N-terminal domain constructs.  As the TIMP-1 
and -2 C-terminal domains alone cannot inhibit MMP activity, these results suggest that the 
observed development defects occurred through a signaling mechanism. In contrast, the 
TIMP-3 C-terminal domain did not disrupt development, or alter any signaling markers 
relative to control embryos. This was consistent with my original hypothesis, which stated 
that the TIMP-3 C-terminal domain would not alter development on its own (only as part of 
the full-length molecule), and was also consistent with evidence from previous in vitro 
experiments which reported that TIMP-3 is sequestered in the ECM through its C-terminal 
domain, and therefore, does not participate in pericellular signaling events (Langton, Barker 
et al. 1998; Yu, Yu et al. 2000; Stetler-Stevenson 2008). 
When comparing data in Chapter 2 (TIMP-2 and -3) and Chapter 3 (TIMP-1), one 
noticeable result was the ability of both the TIMP-1 and -2 C-terminal domains to alter 
MMP-2 and -9 expression at both the mRNA and protein levels. The full-length and N-
terminal domains also had varying abilities to alter MMP expression and activity, which may 
have occurred as an indirect result of MMP inhibition or due to a regulatory feedback 
mechanism within the ECM proteolytic network. However, the fact that the C-terminal 
domains also altered MMP expression and activity levels is suggestive of a unique feedback 
mechanism, whereby the cell can alter relative levels of ECM proteins in direct response to 
TIMP signaling. Surprisingly, TIMP-1 and -2 differed in their abilities to regulate active 
MMP-9 protein. TIMP-2 resulted in increased levels of active MMP-9 relative to control 
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embryos, whereas TIMP-1 decreased active MMP-9 relative to controls, and this decrease 
was most pronounced following overexpression of the C-terminal domain. Though the 
precise mechanisms through which the TIMP-1 and -2 C-domains may regulate MMP-9 
remain unknown, previous studies have also indicated that a special relationship may exist 
between TIMP-1 and pro-MMP-9 (discussed in section 1.5.2.).  TIMP-1 and pro-MMP-9 
have been demonstrated to complex together in the ECM, a function that is mediated by the 
C-terminal domain of TIMP-1 rather than the N-terminal MMP-inhibitory domain 
(Goldberg, Strongin et al. 1992; Itoh and Nagase 1995). More recently, in vitro experiments 
using human cell lines have shown that TIMP-1 and pro-MMP-9 co-localize within the cell 
and are secreted together. This complex has been suggested to be involved in regulation of 
MMP-9 activity and stabilization of the pro-enzyme, and may be found in close proximity to 
the cell surface (Itoh and Nagase 1995; Roderfeld, Graf et al. 2007). My research suggests 
that TIMP-1 may associate with pro-MMP-9 in vivo to regulate MMP-9 activity during 
development.  
Another intriguing aspect of this study was the ability of the TIMP-1 and -2 (but not 
TIMP-3) C-terminal domains to alter specific cell signaling markers in X. laevis embryos. In 
chapter 4, I demonstrated that both the TIMP-1 and -2 C-terminal domains altered RECK 
protein levels relative to controls, and that these trends were mirrored with overexpression of 
the full-length but not N-terminal domain constructs. Again, TIMP-1 and -2 had differing 
effects on RECK expression, suggesting that these two TIMPs may regulate expression and 
activity within the ECM proteolytic network through different mechanisms (Fig. 5.1). 
Although the decrease in RECK protein observed following overexpression of the T2C 
construct was in contrast to current literature, which reported an increase in RECK in human 
endothelial cell lines (Oh, Seo et al. 2004), this has not been recapitulated in any other cell 
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lines or model organisms to date, and could likely vary between species (discussed in detail 
in section 4.4.3.).  The decrease in RECK protein observed in Western blot and IHC studies 
in chapter 4, however, was in agreement with the slight decrease (2-fold decrease relative to 
control embryos) in RECK mRNA observed in chapter 2, which provides further support for 
the idea that the TIMP-2 C-terminal domain can alter RECK expression through an MMP-
independent mechanism. In opposition, the TIMP-1 C-terminal domain resulted in increased 
RECK protein (Fig. 5.1). Although a direct signaling mechanism for TIMP-1 mediated 
regulation of RECK has not previously been reported, TIMP-1 is unique with respect to the 
other TIMPs as in vitro experiments have shown that TIMP-1 can translocate into the nucleus 
(Ritter, Garfield et al. 1999). While the nuclear functions of TIMP-1 remain unknown, to my 
knowledge, nuclear localization has never been demonstrated for any of the other TIMPs. In 
addition, several studies have reported that increased RECK is associated with decreases 
MMP-9 mRNA levels as well as secretion of MMP-9 protein (Takahashi, Sheng et al. 1998; 
Chang, Hung et al. 2008; Takagi, Simizu et al. 2009). This is in agreement with my data, as I 
have shown that while RECK protein is elevated, MMP-9 mRNA and protein are 
downregulated at the same developmental stage. These trends are most pronounced following 
overexpression of the TIMP-1 C-terminal domain. Taken together, these studies highlight the 
complexity of the ECM proteolytic network in vivo, and indicate that TIMP-1 may be an 
important regulator of this network during development, and may have important regulatory 
functions that have yet to be discovered. 
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Fig. 5.1. Model of TIMP signaling during X. laevis development. TIMP-1 binds unknown 
receptors through its C-terminal domain to increase active caspase-3 levels and/or RECK 
protein levels. TIMP-2 binds to unknown receptors through its C-terminal domain to 
decrease RECK protein levels. TIMP-3 remains sequestered in the ECM and has no 
independent signaling mechanism during X. laevis development. TIMP C-terminal domain 
signaling ability is dependent on relative levels of MMPs and other binding partners in the 
ECM, which sequester TIMPs away from the cell surface. 
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In addition, the TIMP-1 full-length and C-terminal domains were demonstrated to 
significantly increase caspase-3 activity in X. laevis embryos, and this association was not 
demonstrated with the TIMP-1 N-terminal domains or with any of the other TIMP constructs 
(Fig. 5.1). Caspase-3 was used as an indicator of apoptosis, as active caspase-3 is normally 
considered an important effector in apoptotic pathways. My results were in contrast to reports 
in the literature, which have demonstrated using several different cell lines that TIMP-1 
suppressed rather than promoted apoptosis (Guedez, Stetler-Stevenson et al. 1998; 
Berditchevski and Odintsova 1999; Li, Fridman et al. 1999; Guedez, Mansoor et al. 2001; 
Jung, Liu et al. 2006). Remarkably, however, a recent study using hematopoietic cells in 
culture has reported that TIMP-1 can indeed lead to increased activation of caspase-3, and 
that this activation is not associated with increased apoptotic cell death (Dasse, Bridoux et al. 
2007). Instead, in this model, increased activation of caspase-3 resulted in cell differentiation 
through activation of MEK1, MEK6, and p38α (Dasse, Bridoux et al. 2007). It remains 
unclear whether the increase in caspase-3 activation that I observed in association with 
overexpression of the TIMP-1 C-terminal domain is indicative of enhanced apoptosis or cell 
differentiation. While further studies are needed to investigate additional markers of both 
pathways, my research has emphasized that the C-terminal domain, particularly of TIMP-1, 
may potentially play intricate roles in the regulation of development. 
5.3 Limitations of this Research and Future Studies 
The major limitation of this study was the lack of mechanistic data regarding how 
TIMP C-terminal domain signaling altered proteolytic gene expression and activity, or cell 
signaling indicators. Though my research is highly suggestive of a C-terminal signaling 
function for TIMP-1 and -2, I did not investigate the specific receptors in X. laevis embryos 
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associated with the observed changes in caspase-3 or proteolytic markers. While in vitro 
studies have identified several cell surface binding partners for TIMP-1 and -2 C-terminal 
domains, receptors and pathways vary with cell type. Indeed, there may be several cell 
surface binding partners for TIMPs in X. laevis, which may vary not only between the 
TIMPs, but also in different developing tissues and/or at different developmental stages.  
As the research presented in this thesis was the first study of TIMP domain function 
during development, I focused mainly on global changes within the whole embryo. I also 
focused solely on organogenesis (stage 30 in development), at which time many 
differentiation and remodeling events occur. A consequence of this approach, however, was 
that I was only able to observe large-scale changes at one particular developmental time 
point. A broader examination of TIMP domain function across other developmental stages, 
such as neurulation and gastrulation, would improve our understanding of TIMP signaling, as 
well as our understanding of how changes in gene expression may be correlated with changes 
in protein levels and activities throughout development. Furthermore, in order to better 
comprehend the mechanisms through which the N- and C-terminal TIMP domains manifest 
their effects, a more detailed analysis of changes in the expression patterns of TIMPs, MMPs, 
and various signaling markers across different tissue types throughout development is 
warranted. This analysis would also provide an indication of whether different tissues have 
distinct abilities to respond to TIMP C-terminal domain signals.  
Future studies may use morpholinos to observe the consequences of TIMP 
knockdown during X. laevis development, compared with overexpression of the full-length 
constructs. Rescue experiments, whereby co-injecting MMP(s) along with TIMP N-terminal 
domains would be useful in attempting to attenuate the effects of N-terminal domain 
overexpression vs. C-terminal domain overexpression. Finally, co-localization and co-
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immunoprecipitation experiments should be used to identify cell surface binding partners for 
the TIMP C-terminal domains. Examination of changes in additional signaling markers may 
help link the individual TIMP C-terminal domains with specific changes in signaling 
pathways in order to tease apart the mechanisms behind the opposing effects of T1C vs. T2C 
overexpression. 
5.4 Conclusions  
Much of the current understanding regarding TIMP function during development has 
been inferred from in vitro cell culture experiments using controlled, and therefore artificial 
conditions. While the significance of these studies cannot be devalued as they have 
considerably progressed the current understanding of ECM dynamics, studies focusing on in 
vivo regulation of these molecules have been very limited in comparison. Although MMPs 
have been fairly well characterized during development, the discovery of the C-terminal 
domain functions of TIMPs has made understanding the interactions between these proteins 
much more complicated (even in cell culture). The fact that TIMPs are now known to have 
both pro- and anti-tumorigenic properties, has made TIMPs a hot topic for cancer research. 
Consequently, investigation of TIMP C-terminal domain function has been carried out almost 
exclusively using transformed cancer cell lines. The signaling pathways, however, that 
TIMPs have been associated with in cancer progression are also important in the regulation 
of development. The research presented in this thesis has been the first comprehensive 
comparison of TIMP domain function in vivo. Additionally, I have provided the first 
evidence that TIMPs have MMP-independent functions during development. Given the ever-
increasing importance of the TIMP C-terminal domains in disease, I believe that these 
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proteins will also prove to be important regulators of developmental events as new and 
interesting roles for the C-terminal domains are discovered. 
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Appendix A: 
 
 
Xenopus laevis TIMP-1 coding sequence (Accession number: KF018236) 
 
 
  1 atgttgtaccttgtggttgtgctggttctagggtgcctcagccag 
 
 46 gaggtgttggggtgcagctgtggacgtaggcacccccagtctgca 
 
 91 tactgcagtgcagattttgttattcgagggagattcattggaaag 
 
136 acccagtacaagacagaagagcagggcagagtgaaatatgagatc 
 
181 aaaactactaagatctttaaggcccctcaaggaatggacgacata 
 
226 cagtttctcagcaccccatcaatggaaagcatgtgcggctacgag 
 
271 cacgtcctctccaacaagagccaggccttcctcattacagggcat 
 
316 gcggtgaatggtaacttggtaatcgaccagtgtaacttcattgtt 
 
361 ccttgggcctcactaactaccgcccagaagaggggcttcgaggag 
 
406 gtgtatcgcaaagcctgttcctgcaacatcgtcccctgctatggt 
 
451 ggtagctgctccctggagtcggacagccagtgcctttggaccgat 
 
496 gtactggtgcactggcaggagcccctcaatggctcccagtccaaa 
 
541 tacatggcctgcgttgaccagggcaatggtctgtgcacatgggag 
 
586 tcccagaagcccagcgtcatcgctgctaggaataaagaggcacag 
 
631 tctgctgccacaacacaataa 651  
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Appendix B: 
 
 
 
 
 
 
 
 
Fig. B.1. Schematic X. laevis embryo at developmental stage 30. Adapted from Nieuwkoop 
and Faber, 1956.  
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Appendix C: 
 
 
 
Fig. C.1. Phenotypic effects of overexpression of TIMP C-terminal constructs. Following 
injection, photographs were taken of representative embryos at stage 30. Microinjection of 
TIMP-1 (A) and TIMP-2 (B) C-terminal domain constructs resulted in head and neural tube 
defects. Overexpression of the TIMP-3 (C) C-terminal domain produced phenotypically 
normal embryos. Actual size of all embryos is 1 mm in diameter. Images are of 
representative embryos where results were consistent in at least 3 independent sets of 
experiments, and a minimum of 100 embryos were injected and monitored for each replicate. 
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Appendix D: 
 
!! Ef#1α& MMP#2& MMP#9& RECK& INTG&Beta1&
CONT& 16.25! 24.52! 25.09! 26.28! 23.52!
T2FL& 15.99! 24.71! 25.01! 26.22! 23.35!
T2N& 16.24! 25.38! 27.03! 26.90! 23.87!
T2C& 14.81! 30.10! 31.10! 27.17! 24.33!
&& !! !! !! !! !!
CONT& 18.84! 29.06! 27.91! 27.03! 26.08!
T3FL& 18.83! 33.54! 32.03! 28.15! 25.85!
T3N& 18.72! 31.87! 27.36! 28.77! 25.61!
T3C& 18.55! 31.42! 28.28! 26.68! 27.40!
 
Table D.1. Real-time PCR CT values for embryos injected with TIMP-2 and -3 
constructs. Real-time PCR was used to measure the changes in transcript levels following 
the injection of 4 ng of TIMP-2 full-length (T2FL), N-terminal (T2N), or C-terminal (T2C), 
or TIMP-3 full-length (T3FL), N-terminal (T3N), or C-terminal (T3C) mRNA constructs into 
X. laevis embryos at the one cell stage. The CT value represents the PCR cycle at which the 
gene of interest passed a defined threshold. Changes in transcript levels were measured 
relative to Ef-1α and normalized to CONT (control, uninjected) embryos. INTG Beta 1 
represents β1 integrin. CT values are representative of one experiment. 
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